[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1377
1. Crum-Cianflone NF, Hullsiek KH, Marconi VC, Ganesan A, Weintrob A, Barthel RV, Agan BK, Infectious Disease Clinical Research Program HIV Working Group: Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS; 2010 Feb 20;24(4):535-43
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancers among HIV-infected persons: HAART is not slowing rising incidence.
  • OBJECTIVE: To evaluate the incidence rates of anal cancer over the HIV epidemic and assess the impact of HAART use on anal cancer events.
  • METHODS: We evaluated the incidence of and factors associated with anal cancer using longitudinal data from the prospective U.S.
  • RESULTS: Among 4506 HIV-infected men with 37 806 person-years of follow-up, anal cancer rates (per 100 000 person-years) increased five-fold, from 11 in the pre-HAART to 55 in the HAART era (P = 0.02).
  • At cancer diagnosis (n = 19), median age was 42 years, median CD4 cell count was 432 cells/microl, 74% had a CD4 nadir cell count less than 200 cells/microl, 42% had a prior AIDS event, and 74% had received HAART.
  • From separate models, prior AIDS event (hazard ratio 3.88, P = 0.01) and lower CD4 nadir (hazard ratio 0.85 per 50 cell, P = 0.03) were associated with anal cancer, with a trend for a history of gonorrhea (hazard ratio 2.43, P = 0.07).
  • Duration of HAART use was not associated with a reduced risk of anal cancer (hazard ratio 0.94, P = 0.42).
  • CONCLUSION: Incidence rates of anal cancer have progressively increased during the HIV epidemic.
  • Persons with a longer duration of HIV infection have a substantially higher rate of anal cancer.
  • As HIV-infected persons are experiencing longer life expectancies and HAART does not appear protective of anal cancer, studies on preventive strategies are needed.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr. 2001 Mar 1;26(3):256-62 [11242198.001]
  • [Cites] Cancer. 2009 Feb 1;115(3):524-30 [19127538.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):611-6 [3524788.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S42-8 [10430218.001]
  • [Cites] Ann Intern Med. 1999 Oct 5;131(7):502-6 [10507958.001]
  • [Cites] Sex Transm Dis. 2005 May;32(5):314-20 [15849533.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Am J Surg. 2005 Nov;190(5):732-5 [16226949.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):451-5 [16280701.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] AIDS. 2007 Jul 11;21(11):1457-65 [17589192.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):73-81 [18066626.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):474-9 [18202423.001]
  • [Cites] Sex Transm Dis. 2008 Feb;35(2):197-202 [18216727.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Curr HIV/AIDS Rep. 2008 May;5(2):78-85 [18510893.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] Lancet. 2008 Jul 26;372(9635):293-9 [18657708.001]
  • [Cites] J Public Health (Oxf). 2008 Sep;30(3):293-304 [18559368.001]
  • [Cites] Ann Intern Med. 2008 Sep 2;149(5):300-6 [18765699.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2892-900 [18980293.001]
  • [Cites] AIDS. 2009 Jan 2;23(1):41-50 [19050385.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):61-4 [12085257.001]
  • (PMID = 19926961.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / HU0001-05-2-0011; United States / NIAID NIH HHS / AI / Y01 AI005072; United States / PHS HHS / / HU0001-05-2-0011
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS203436; NLM/ PMC3132114
  • [Investigator] Banks S; Bavaro M; Chun H; Decker C; Eberly L; Eggleston C; Hairston H; Hawkes C; Johnson A; Landrum M; Lifson A; Merritt S; O'Connell R; Okulicz J; Peel S; Polis M; Powers J; Tramont E; Whitman T; Wortmann G; Zapor M
  •  go-up   go-down


2. Stelzer MK, Pitot HC, Liem A, Lee D, Kennedy GD, Lambert PF: Rapamycin inhibits anal carcinogenesis in two preclinical animal models. Cancer Prev Res (Phila); 2010 Dec;3(12):1542-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapamycin inhibits anal carcinogenesis in two preclinical animal models.
  • The incidence of anal cancer is increasing especially among HIV-infected persons in the HAART era.
  • Treatment of this cancer is based upon traditional chemoradiotherapeutic approaches, which are associated with high morbidity and of limited effectiveness for patients with high-grade disease.
  • The mammalian target of rapamycin (mTOR) pathway has been implicated in several human cancers, and is being investigated as a potential therapeutic target.
  • In archival human anal cancers, we observed mTOR pathway activation.
  • To assess response of anal cancer to mTOR inhibition, we utilized two newly developed mouse models, one in which anal cancers are induced to arise in HPV16 transgenic mice and the second a human anal cancer xenograft model.
  • We saw significant changes in the overall incidence of tumors, and tumor growth rate was also reduced.
  • Using both the transgenic mouse and human anal xenograft mouse models, we studied the therapeutic effect of rapamycin on preexisting anal cancer.
  • Rapamycin was found to significantly slow, if not stop, the growth of both mouse and human anal cancers.
  • As has been seen in other cancers, rapamycin treatment led to an activation of the MAPK pathway.
  • These results provide us cause to pursue further the evaluation of rapamycin as a therapeutic agent in the control of anal cancer.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9953-61 [16267020.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Dec;3(12):1534-41 [20947489.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14152-7 [16959885.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9393-400 [17018593.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10040-7 [17047067.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2160-8 [17332346.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2281-9 [17404113.001]
  • [Cites] Oncogene. 2007 May 17;26(23):3321-8 [17130828.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):4964-73 [17785546.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11585-93 [18089787.001]
  • [Cites] J Invest Dermatol. 2008 Apr;128(4):980-7 [17914450.001]
  • [Cites] Cancer Res. 2008 Apr 15;68(8):2622-31 [18413729.001]
  • [Cites] Mol Carcinog. 2008 Jun;47(6):446-57 [18058806.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Jul;62(2):305-13 [17912526.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] J Clin Invest. 2008 Sep;118(9):3065-74 [18725988.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Sep;6 Suppl 5:S1-20; quiz S21-2 [18926092.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3373-81 [11309295.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4862-71 [12941807.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):9094-103 [14645521.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8173-80 [14678972.001]
  • [Cites] J Antibiot (Tokyo). 1975 Oct;28(10):721-6 [1102508.001]
  • [Cites] Can J Physiol Pharmacol. 1977 Feb;55(1):48-51 [843990.001]
  • [Cites] Immunology. 1991 Apr;72(4):544-9 [1709916.001]
  • [Cites] Cancer Res. 1994 Feb 15;54(4):903-7 [7508822.001]
  • [Cites] Circ Res. 1995 Mar;76(3):412-7 [7532117.001]
  • [Cites] J Virol. 1996 Mar;70(3):1873-81 [8627712.001]
  • [Cites] J Virol. 1999 Jul;73(7):5887-93 [10364340.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2490-5 [15699322.001]
  • [Cites] J Virol. 2005 Apr;79(7):3938-48 [15767396.001]
  • [Cites] Cell. 2005 Mar 25;120(6):747-59 [15797377.001]
  • [Cites] Curr Opin Cell Biol. 2005 Dec;17(6):596-603 [16226444.001]
  • [Cites] Cancer Res. 2008 Dec 1;68(23):9928-34 [19047174.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Jan;2(1):27-36 [19139015.001]
  • [Cites] Clin Cancer Res. 2009 Jan 15;15(2):589-96 [19147764.001]
  • [Cites] Int J Cancer. 2009 May 15;124(10):2375-83 [19189402.001]
  • [Cites] Nat Rev Immunol. 2009 May;9(5):324-37 [19390566.001]
  • [Cites] Cancer Res. 2009 May 15;69(10):4407-14 [19435895.001]
  • [Cites] Cancer Res. 2009 May 15;69(10):4159-66 [19435901.001]
  • [Cites] Cancer Res. 2009 Jul 15;69(14):5656-63 [19584294.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19467-72 [19901334.001]
  • [Cites] Semin Oncol. 2009 Dec;36 Suppl 3:S46-58 [19963100.001]
  • [Cites] Cancer Res. 2010 Apr 1;70(7):2924-31 [20332225.001]
  • [Cites] Cancer Res. 2010 Jun 15;70(12):5064-73 [20530688.001]
  • [Cites] Int J Oncol. 2010 Oct;37(4):1001-10 [20811722.001]
  • [Cites] Virology. 2010 Nov 10;407(1):60-7 [20797753.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1183-9 [16731750.001]
  • (PMID = 21149330.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA090217-07; United States / NCI NIH HHS / CA / U01 CA141583; United States / NCI NIH HHS / CA / CA141583-03; United States / NCI NIH HHS / CA / CA141583-02; United States / NIDCR NIH HHS / DE / R01 DE017315-03; United States / NCI NIH HHS / CA / CA090217-07; United States / NCI NIH HHS / CA / T32 CA090217-06; United States / NCI NIH HHS / CA / U01 CA141583-03; United States / NCI NIH HHS / CA / U01 CA141583-01; United States / NIDCR NIH HHS / DE / R01 DE017315-04; United States / NCI NIH HHS / CA / CA090217-06; United States / NCI NIH HHS / CA / CA141583-01; United States / NCI NIH HHS / CA / T32 CA090217-05; United States / NCI NIH HHS / CA / CA090217-05; United States / NIDCR NIH HHS / DE / R01 DE017315; United States / NIDCR NIH HHS / DE / R01 DE017315-05; United States / NCI NIH HHS / CA / T32 CA090217; United States / NCI NIH HHS / CA / U01 CA141583-02; United States / NCI NIH HHS / CA / R01 CA098428
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Carcinogens; 0 / E6 protein, Human papillomavirus type 16; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / Repressor Proteins; 0 / oncogene protein E7, Human papillomavirus type 16; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ NIHMS249482; NLM/ PMC3058330
  •  go-up   go-down


3. Ramamoorthy S, Liu YT, Luo L, Miyai K, Lu Q, Carethers JM: Detection of multiple human papillomavirus genotypes in anal carcinoma. Infect Agent Cancer; 2010;5:17
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of multiple human papillomavirus genotypes in anal carcinoma.
  • Infection with human papillomavirus (HPV) is a major risk factor for development of anal squamous cell carcinoma.
  • Despite over 100 genotypes of the virus, HPV 16 and 18 are considered pathogenic as they are seen in the majority of cervical and anal cancers.
  • We aimed to determine the accuracy of our microarray in anal cancer DNA for HPV genotypes compared to the DNA sequencing gold standard.
  • METHODS: We utilized a sensitive microarray platform to classify 37 types of mucosal HPVs including 14 known high-risk and 23 low-risk types based on cervical cancer data.
  • We utilized DNA from pathologically confirmed cases of anal squamous cell carcinoma.
  • RESULTS: HPV was detected in 18/20 (90%) anal cancers.
  • Eighty percent of anal cancers had at least two HPV types.
  • CONCLUSIONS: Microarray technology is an accurate way to screen for various genotypes of HPV in anal cancer, with 100% correlation with genomic DNA detection of HPV.
  • The majority of anal cancers in our study associated with pathogenic HPV 16 and/or 18.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20939896.001).
  • [ISSN] 1750-9378
  • [Journal-full-title] Infectious agents and cancer
  • [ISO-abbreviation] Infect. Agents Cancer
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK067287; United States / NCI NIH HHS / CA / R21 CA137346; United States / NIDDK NIH HHS / DK / R24 DK080506
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2964599
  •  go-up   go-down


Advertisement
4. Rapose A: Human papillomavirus and genital cancer. Indian J Dermatol Venereol Leprol; 2009 May-Jun;75(3):236-43; quiz 243-4
MedlinePlus Health Information. consumer health - HPV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus and genital cancer.
  • Persistent infection with high-risk HPV-types is associated with genital cancers.
  • Smoking and HIV infection have consistently been associated with longer duration of HPV infection and risk for genital cancer.
  • There is an increasing incidence of anal cancers, and a close association with HPV infection has been demonstrated.
  • Receptive anal sex and HIV-positive status are associated with a high risk for anal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19439875.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Number-of-references] 66
  •  go-up   go-down


5. Fradet-Turcotte A, Archambault J: Recent advances in the search for antiviral agents against human papillomaviruses. Antivir Ther; 2007;12(4):431-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infection by human papillomavirus (HPV) is extremely common and associated with the development of benign warts or malignant lesions of the skin and mucosa.
  • Infection by a high-risk (oncogenic) anogenital HPV type, most often through sexual contacts, is the starting point of virtually all cases of cervical cancers and the majority of anal cancers.
  • The same viral types are also increasingly being linked with a subset of head-and-neck and non-melanoma skin cancers.
  • Although prophylactic vaccines are now available to protect against the four types most commonly found in cervical and anal cancers (HPV16 and HPV18) and anogenital warts (HPV6 and HPV11), these neither protect against all genital HPVs nor are of therapeutic utility for already infected patients.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17668552.001).
  • [ISSN] 1359-6535
  • [Journal-full-title] Antiviral therapy
  • [ISO-abbreviation] Antivir. Ther. (Lond.)
  • [Language] ENG
  • [Grant] None / None / / 68885-1; Canada / Canadian Institutes of Health Research / / 68885-1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Proteins; 0 / Viral Proteins
  • [Number-of-references] 192
  • [Other-IDs] NLM/ CAMS5300; NLM/ PMC4646640
  •  go-up   go-down


6. Robb BW, Mutch MG: Epidermoid carcinoma of the anal canal. Clin Colon Rectal Surg; 2006 May;19(2):54-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermoid carcinoma of the anal canal.
  • Anal cancers are rare tumors with only an expected 4000 new diagnoses in 2005.
  • The majority of these are epidermoid or squamous cell cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1153-60 [2599903.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] Br J Surg. 2005 May;92(5):605-14 [15739215.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] Cancer. 1956 May-Jun;9(3):480-8 [13329997.001]
  • [Cites] Arch Surg. 1964 Dec;89:989-94 [14208473.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):127-31 [10219805.001]
  • [Cites] Acta Oncol. 1997;36(8):799-802 [9482685.001]
  • [Cites] Cancer. 1999 Aug 1;86(3):405-9 [10430247.001]
  • [Cites] Dis Colon Rectum. 1998 Dec;41(12):1488-93 [9860327.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1300-2 [9731737.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5 [9169819.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Br J Cancer. 1997;75(5):722-8 [9043031.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1996;8(5):319-22 [8934052.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] J Pathol. 1996 Dec;180(4):378-82 [9014857.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1569-79 [8156483.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 16;86(22):1711-6 [7966400.001]
  • [Cites] Lancet. 1994 Mar 12;343(8898):636-9 [7906812.001]
  • [Cites] N Engl J Med. 1994 Aug 4;331(5):300-2 [8022440.001]
  • [Cites] Obstet Gynecol. 1994 Feb;83(2):205-11 [8290181.001]
  • [Cites] BMJ. 1993 Feb 13;306(6875):419-22 [8461721.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1385-7 [1938540.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):180-9 [1311142.001]
  • [Cites] Arch Surg. 1992 Jun;127(6):741-4 [1317698.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):1014-9 [1846314.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] Gastroenterology. 1988 Jul;95(1):107-11 [2836255.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] N Engl J Med. 1986 Oct 23;315(17):1089-90 [3020406.001]
  • [Cites] Am J Clin Pathol. 1989 Jul;92(1):16-21 [2546419.001]
  • [Cites] J Natl Cancer Inst. 1989 Nov 15;81(22):1726-31 [2810388.001]
  • [Cites] Br J Surg. 1989 Aug;76(8):806-10 [2765832.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):611-6 [3524788.001]
  • [Cites] J Infect Dis. 1990 Aug;162(2):358-61 [1973695.001]
  • [Cites] Cancer. 1984 Jul 1;54(1):114-25 [6326995.001]
  • [Cites] Br J Cancer. 1983 Nov;48(5):629-36 [6639856.001]
  • [Cites] JAMA. 1982 Apr 9;247(14):1988-90 [7062503.001]
  • [Cites] Ann Surg. 1976 Oct;184(4):422-8 [189707.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Dis Colon Rectum. 2004 Jul;47(7):1136-44 [15164245.001]
  • [Cites] Br J Surg. 2002 Nov;89(11):1425-9 [12390386.001]
  • [Cites] Dis Colon Rectum. 2001 Oct;44(10):1496-502 [11598480.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):754-8 [10762748.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1141-51 [2599902.001]
  • (PMID = 20011311.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780104
  • [Keywords] NOTNLM ; Epidermoid cancer / anal canal / squamous cancer
  •  go-up   go-down


7. Stelzer MK, Pitot HC, Liem A, Schweizer J, Mahoney C, Lambert PF: A mouse model for human anal cancer. Cancer Prev Res (Phila); 2010 Dec;3(12):1534-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A mouse model for human anal cancer.
  • Human anal cancers are associated with high-risk human papillomaviruses (HPV) that cause other anogenital cancers and head and neck cancers.
  • As with other cancers, HPV16 is the most common high-risk HPV in anal cancers.
  • We describe the generation and characterization of a mouse model for human anal cancer.
  • This model makes use of K14E6 and K14E7 transgenic mice in which the HPV16 E6 and E7 genes are directed in their expression to stratified squamous epithelia.
  • HPV16 E6 and E7 possess oncogenic properties including, but not limited to, their capacity to inactivate the cellular tumor suppressors p53 and pRb, respectively.
  • Both E6 and E7 were found to be functionally expressed in the anal epithelia of K14E6/K14E7 transgenic mice.
  • To assess the susceptibility of these mice to anal cancer, mice were treated topically with dimethylbenz[a]anthracene (DMBA), a chemical carcinogen that is known to induce squamous cell carcinomas in other sites.
  • Histopathologic analyses confirmed that the HPV16 transgenic mice were increased in their susceptibility to anal cancers and precancerous lesions.
  • Biomarker analyses demonstrated that these mouse anal cancers exhibit properties that are similar to those observed in HPV-positive precursors to human anal cancer.
  • This is the first mouse model for investigating the contributions of viral and cellular factors in anal carcinogenesis, and should provide a platform for assessing new therapeutic modalities for treating and/or preventing this type of cancer.

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):9094-103 [14645521.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4862-71 [12941807.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):263-75 [15137956.001]
  • [Cites] Cancer Res. 1982 Sep;42(9):3519-25 [6286109.001]
  • [Cites] J Pathol. 1990 Jun;161(2):99-103 [2199641.001]
  • [Cites] J Virol. 1996 Mar;70(3):1873-81 [8627712.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4350-4 [8633069.001]
  • [Cites] Nature. 1998 Nov 5;396(6706):84-8 [9817205.001]
  • [Cites] J Virol. 1999 Jul;73(7):5887-93 [10364340.001]
  • [Cites] Br J Surg. 2006 May;93(5):531-8 [16607677.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14152-7 [16959885.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1626-35 [17308103.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4605-19 [17510386.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6106-12 [17616666.001]
  • [Cites] Cancer Cell. 2007 Oct;12(4):313-27 [17936557.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2668-73 [17721920.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11585-93 [18089787.001]
  • [Cites] Mol Cancer. 2008;7:3 [18184435.001]
  • [Cites] Ann Intern Med. 2008 Sep 2;149(5):300-6 [18765699.001]
  • [Cites] Int J Cancer. 2009 May 15;124(10):2375-83 [19189402.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] Mod Pathol. 2010 Jan;23(1):144-50 [19838162.001]
  • [Cites] J Am Acad Dermatol. 2010 Sep;63(3):490-8 [20006407.001]
  • [Cites] Br J Dermatol. 2010 Jun;162(6):1269-77 [20184584.001]
  • [Cites] Virology. 2000 Feb 15;267(2):141-50 [10662610.001]
  • [Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8173-80 [14678972.001]
  • (PMID = 20947489.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098428-08; United States / NCI NIH HHS / CA / P01 CA022443-330006; United States / NCI NIH HHS / CA / R01 CA098428-09; United States / NCI NIH HHS / CA / U01 CA141583; United States / NCI NIH HHS / CA / P01 CA022443-320006; United States / NCI NIH HHS / CA / CA098428-08; United States / NCI NIH HHS / CA / CA022443-330006; United States / NCI NIH HHS / CA / CA141583-02; United States / NCI NIH HHS / CA / U01 CA141583-01; United States / NIDCR NIH HHS / DE / R01 DE017315-04; United States / NCI NIH HHS / CA / CA141583-01; United States / NCI NIH HHS / CA / CA022443-320006; United States / NIDCR NIH HHS / DE / R01 DE017315; United States / NIDCR NIH HHS / DE / R01 DE017315-05; United States / NCI NIH HHS / CA / CI T32 CA090217; United States / NCI NIH HHS / CA / T32 CA090217; United States / NCI NIH HHS / CA / U01 CA141583-02; United States / NCI NIH HHS / CA / P01 CA022443; United States / NCI NIH HHS / CA / R01 CA098428
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / E6 protein, Human papillomavirus type 16; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / Repressor Proteins; 0 / oncogene protein E7, Human papillomavirus type 16; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  • [Other-IDs] NLM/ NIHMS211621; NLM/ PMC3006089
  •  go-up   go-down


8. Wilkes G, Hartshorn K: Colon, rectal, and anal cancers. Semin Oncol Nurs; 2009 Feb;25(1):32-47
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon, rectal, and anal cancers.
  • OBJECTIVES: To review the incidence, risk factors, staging, diagnosis, and treatment of colon, rectal, and anal cancers, as well as nursing care associated with managing patients diagnosed with these malignancies.
  • CONCLUSIONS: Significant advances in the management of colon, rectal, and anal cancers in the past decade have extended patient survival.
  • [MeSH-major] Anus Neoplasms. Carcinoma, Squamous Cell. Colonic Neoplasms. Rectal Neoplasms
  • [MeSH-minor] Humans. Neoplasm Staging. Risk Factors

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19217504.001).
  • [ISSN] 0749-2081
  • [Journal-full-title] Seminars in oncology nursing
  • [ISO-abbreviation] Semin Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 92
  •  go-up   go-down


9. Jeffreys M, Rachet B, McDowell S, Habib AG, Lepage C, Coleman MP: Survival from rectal and anal cancers in England and Wales, 1986-2001. Eur J Cancer; 2006 Jul;42(10):1434-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival from rectal and anal cancers in England and Wales, 1986-2001.
  • The aim of this study was to investigate the effects of tumour and patient characteristics on trends in the survival of patients with cancer of the anus or rectum in England and Wales.
  • Relative survival up to 5 years after diagnosis was estimated, using deprivation-specific life tables.
  • Generalised linear models were used to estimate relative excess risks of death, adjusted for patient and tumour characteristics.
  • The results showed that 5-year relative survival was higher in women, younger patients and more affluent patients, and higher for anal cancer than rectal cancer.
  • This trend was not explained by changes in the distribution of age, anatomical site, morphology or deprivation.
  • The trend was more marked in younger and more affluent patients, and for adenocarcinoma and epidermoid carcinoma than for tumours with other morphology.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anus Neoplasms / mortality. England / epidemiology. Female. Humans. Middle Aged. Survival Analysis. Wales / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16600590.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


10. Park J, Neuman HB, Weiser MR, Wong WD: Randomized clinical trials in rectal and anal cancers. Surg Oncol Clin N Am; 2010 Jan;19(1):205-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized clinical trials in rectal and anal cancers.
  • This article reviews randomized clinical trials (RCTs) published between April 2001 and November 2008 on the management of patients with rectal cancer.
  • In total, the authors reviewed 78 RCTs on therapy for rectal cancer.
  • The article discusses the major RCTs and relevant findings that have impacted clinical management most and includes most but not all RCTs on therapy for rectal cancer published during this period.
  • [MeSH-major] Anus Neoplasms / therapy. Randomized Controlled Trials as Topic. Rectal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19914567.001).
  • [ISSN] 1558-5042
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 89
  •  go-up   go-down


11. Cotte E, Lifante JC, Cherki S, François Y, Vignal J, Peix JL, Glehen O: [Rectal amputation by pure perineal approach with laparoscopic colostomy: a palliative therapeutic option for low rectal or anal cancers for elderly patients with multiple comorbidities]. Ann Chir; 2006 Feb;131(2):100-3
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rectal amputation by pure perineal approach with laparoscopic colostomy: a palliative therapeutic option for low rectal or anal cancers for elderly patients with multiple comorbidities].
  • [Transliterated title] Amputation du rectum par voie périnéale pure avec colostomie coelio-assistée: une option thérapeutique palliative pour les cancers du bas rectum ou de l'anus chez le sujet âgé ou multitaré.
  • Rectal syndrome caused by locoregional evolution of low rectal cancers and anal cancers is prevented and treated by surgical resection.
  • The palliative treatment of low rectal cancers or anal cancers combining rectal amputation by pure perineal approach with laparoscopic colostomy may be an interesting therapeutic option for patients who cannot undergoing aggressive carcinologic surgical treatment.
  • [MeSH-major] Anus Neoplasms / surgery. Colostomy / methods. Laparoscopy. Palliative Care. Rectal Neoplasms / surgery. Rectum / surgery

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16430855.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


12. Capdevila J, Ramos FJ, Macarulla T, Elez E, Ruiz-Echarri M, Perez-Garcia J, Tabernero J: Development of new drug strategies in infrequent digestive tumors: esophageal, biliary tract, and anal cancers. Curr Opin Oncol; 2009 Jul;21(4):374-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of new drug strategies in infrequent digestive tumors: esophageal, biliary tract, and anal cancers.
  • The increasing development of new targeted therapies in human cancer has also impacted in these rare gastrointestinal malignancies providing a wide range of possibilities in the design of future clinical trials.
  • The results of the biggest phase III trial in locally advanced anal carcinoma have been recently published.
  • Finally, the inhibition of epidermal growth factor receptor has also showed promising activity in anal carcinomas.
  • SUMMARY: Recent advances in the knowledge of molecular mechanism of carcinogenesis have led to meaningful changes in the management of gastrointestinal cancers.
  • Although the major advances in targeted therapy have been introduced in the treatment of colorectal cancer, new interesting approaches have been reported in less frequent gastrointestinal tumors such as esophageal, biliary tract, and anal canal carcinoma opening a new hope in the treatment of these rare tumors in the molecular targeted therapy era.
  • [MeSH-minor] Angiogenesis Inhibitors / therapeutic use. Anus Neoplasms / blood supply. Anus Neoplasms / drug therapy. Anus Neoplasms / enzymology. Biliary Tract Neoplasms / blood supply. Biliary Tract Neoplasms / drug therapy. Biliary Tract Neoplasms / enzymology. Drug Delivery Systems. Esophageal Neoplasms / blood supply. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / enzymology. Humans. Neovascularization, Pathologic / drug therapy. Receptor, Epidermal Growth Factor / antagonists & inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19412097.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 65
  •  go-up   go-down


13. Markos AR: The presentation of anogenital cancers as sexually transmissible infection: a case for vigilance. Sex Health; 2007 Mar;4(1):79-80
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The presentation of anogenital cancers as sexually transmissible infection: a case for vigilance.
  • There is sporadically published literature reporting cases of vulval, penile and anal cancers presenting at genitourinary medicine clinics.
  • The recent referral of a series of cases, by medical practitioners, as anogenital warts, which were later diagnosed as vulval, penile and anal cancers, is alarming.
  • [MeSH-major] Anus Neoplasms / diagnosis. Condylomata Acuminata / diagnosis. Penile Neoplasms / diagnosis. Vulvar Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Referral and Consultation

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Genital Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17382045.001).
  • [ISSN] 1448-5028
  • [Journal-full-title] Sexual health
  • [ISO-abbreviation] Sex Health
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


14. Zucchini C, Concu M, Martini F, Morelli C, Salfi N, Carinci P, Tognon M, Caramelli E: FHIT oncosuppressor gene expression profile in human anal cancers. Int J Biol Markers; 2007 Jan-Mar;22(1):39-42
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FHIT oncosuppressor gene expression profile in human anal cancers.
  • The FHIT gene, a member of the histidine triad gene family, is a tumor suppressor gene exhibiting deletions in the majority of human cancers.
  • Little is known about the molecular mechanisms involved in malignant transformation of the lining cells of the anus.
  • In this study FHIT gene expression was investigated in this particular kind of human cancer.
  • FHIT expression was comparatively analyzed at the mRNA level, by RT-PCR, in squamous anal cancers, normal anal tissue and peripheral blood samples. cDNA analyses showed variability in FHIT transcripts, without apparent effects on the predicted amino acid sequence.
  • Our data indicate that the FHIT mRNA detected in anal cancers and in normal samples is heterogeneous.
  • Immunohistochemical data suggest that the Fhit protein is expressed only in a fraction of the tumor cells, while it is strongly expressed in the epithelial cells of glands of the normal anal mucosa.
  • The absence or poor expression of the Fhit protein in anal cancers suggests a role for this tumor suppressor gene product, as a risk factor, in the onset of this human cancer, as reported before for other human gastrointestinal tumors.
  • [MeSH-major] Acid Anhydride Hydrolases / biosynthesis. Anus Neoplasms / metabolism. Neoplasm Proteins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17393360.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


15. Chaturvedi AK: Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health; 2010 Apr;46(4 Suppl):S20-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beyond cervical cancer: burden of other HPV-related cancers among men and women.
  • Human papillomavirus (HPV) infection is a necessary cause of cervical cancer, and is etiologically associated with a subset of cancers of the anus, oropharynx, penis, vagina, and vulva.
  • Current data indicate that HPV infection is potentially associated with 90%-93% of anal cancers, 12%-63% of oropharyngeal cancers, 36%-40% of penile cancers, 40%-64% of vaginal cancers, and 40%-51% of vulvar cancers.
  • HPV infection accounts for up to 492,800 cervical cancers and 97,215 cases of noncervical HPV-related cancers worldwide during 2002, including up to 50,780 cancers among men (13,485 anal cancers, 26,775 oropharyngeal cancers, and 10,520 penile cancers) and up to 46,435 cancers among women (14,787 anal cancers, 6,048 oropharyngeal cancers, and 25,600 vaginal/vulvar cancers).
  • In the United States annually (1998-2003), up to 10,846 cervical cancers, 4,753 noncervical cancers among men, and 4,128 noncervical cancers among women are potentially attributable to HPV infection.
  • Incidence rates for cervical cancer have declined significantly during the past 30 years in the United States, consistent with the success of Pap smear screening.
  • However, incidence rates for anal, oropharyngeal, and vulvar cancers have increased substantially in recent years.
  • The high proportion of cervical and noncervical cancers caused by HPV types 16 and 18, that is, 70%-76% for cervical cancers and 63%-95% for noncervical cancers, underscores the potential for prevention of a majority of cervical as well as noncervical HPV-related cancers through prophylactic HPV vaccination.
  • [MeSH-major] Anus Neoplasms / epidemiology. Cost of Illness. Genital Neoplasms, Female / epidemiology. Oropharyngeal Neoplasms / epidemiology. Papillomavirus Infections / epidemiology. Penile Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20307840.001).
  • [ISSN] 1879-1972
  • [Journal-full-title] The Journal of adolescent health : official publication of the Society for Adolescent Medicine
  • [ISO-abbreviation] J Adolesc Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  •  go-up   go-down


16. Eng C, Chang GJ, Das P, Rodriguez-Bigas M, Skibber JM, Qiao W, Rosner GL, Ukegbu LT, Wolff RA, Crane CH: Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal. J Clin Oncol; 2009 May 20;27(15_suppl):4116

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal.
  • : 4116 Background: Definitive therapy for squamous cell carcinoma (SCC) of the anal canal consists of external beam radiotherapy with concurrent 5-fluorouracil and mitomycin C or cisplatin.
  • The purpose of this study was to evaluate the tolerability and efficacy of XELOX-XRT as definitive treatment for anal cancer.
  • METHODS: Patients with histologically proven SCC of the anal canal, AJCC Stage II-IIIB (T<sub>2-4</sub> or N+M<sub>0</sub>), ECOG PS 0-1, HIV<sup>-</sup>, and no prior therapy were eligible for XELOX-based chemoradiotherapy.
  • CONCLUSIONS: The combination of capecitabine, oxaliplatin, and radiation therapy (XELOX-XRT) is effective for locally advanced squamous cell carcinoma of the anal canal.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961220.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. James R, Wan S, Glynne-Jones R, Sebag-Montefiore D, Kadalayil L, Northover J, Cunningham D, Meadows H, Ledermann J, National Cancer Research Institute (NCRI) ACT II Trial Management Group: A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II). J Clin Oncol; 2009 May 20;27(15_suppl):LBA4009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963297.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Yap JC, Yang GY, Fakih M, Mashtare T, Bullard Dunn K, Kuvshinoff BW, Smith J, Khushalani NI, Gibbs JF: Primary adenocarcinoma of the anus: a 22-year SEER population database analysis. J Clin Oncol; 2009 May 20;27(15_suppl):e15072

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma of the anus: a 22-year SEER population database analysis.
  • : e15072 Background: Most anal canal cancers consist of squamous cell carcinoma (SCCA).
  • Adenocarcinoma (AdenoCa) is rare and accounts for approximately 10% of anal cancers.
  • METHODS: The search of the SEER database revealed 1,008 pts who had pathologically confirmed anal cancers with either SCCA or AdenoCa.
  • All pts had single diagnosis of anal cancer with localized disease without nodal involvement.
  • Within the SCCA group, 14 (1.5%) had abdominoperineal resection (APR) in combination with external beam RT, and 795 (83.3%) had RT only with non-APR local surgical treatment inclusive of excision.
  • Remaining 145 SCCA pts (15.2%) had non-APR local surgical treatment only without RT or had no treatment.
  • Within the AdenoCa group, 10 (18.5%) had APR in combination with external beam RT, and 21 (38.9%) had RT only with non-APR local surgical treatment inclusive of excision.
  • Remaining 23 AdenoCa pts (42.6%) had non-APR local surgical treatment only without RT.
  • On the other hand, among the AdenoCa subset, pts who had APR had better 10-yr OS than RT pts (53.8% vs. 0%, p=0.03) Conclusions: For localized anal SCCA, RT yielded equivalent overall survival as compared to APR.
  • On the other hand, pts with localized anal adenoCa appeared to do worse when APR was omitted.
  • Omission of APR in pts with anal canal adenoCa should be cautiously weighed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964572.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Mita MM, Tolcher A, Gordon MS, Rosen L, Mita A, Fine G, Choy G, Berk G: A phase Ib dose-escalation study of orally administered MP-470, a multi-kinase inhibitor and supressor of Rad51, in combination with carboplatin doublet containing regimens shows activity in highly refractory solid tumor patients. J Clin Oncol; 2009 May 20;27(15_suppl):e13511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase Ib dose-escalation study of orally administered MP-470, a multi-kinase inhibitor and supressor of Rad51, in combination with carboplatin doublet containing regimens shows activity in highly refractory solid tumor patients.
  • : e13511 Background: MP-470 (MP) is an oral multi-targeted tyrosine kinase inhibitor which inhibits a number of validated tumor targets including c-kit, flt3, and PDGFα.
  • MP470 targets cancer cells by disrupting DNA repair, an important survival pathway in many human cancers.
  • Results presented herein are from two arms of a phase-Ib five arm trial of MP combined with standard of care (SOC) anti- cancer therapies.
  • Adults with ECOG PS of 0-2 and malignant disease appropriate for SOC regimens consisting of paclitaxel/carboplatin (PC), carboplatin/etoposide (CE), topotecan, docetaxel, and erlotinib were enrolled.
  • Six PRs (2 neuroendocrine, 2 SCLC, 1 NSCLC, 1 small cell of anal canal) and 3 SDs (≥ 4 cycles) was observed.
  • CONCLUSIONS: MP470 combined with carboplatin-containing regimens may promote tumor regression and may also sensitize/resensitize tumors to the anticancer effects of such agents.
  • An amendment will be issued to collect tumor tissue biopsy at baseline and during treatment to adequately evaluate DNA damage in tumor tissue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961308.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. You YN, Larson DW, Dozois EJ, Nelson H, Antpack Filho E, Klein K, Miller RC: Multimodality salvage therapy for anal cancer failing standard chemoradiation. J Clin Oncol; 2009 May 20;27(15_suppl):e15635

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality salvage therapy for anal cancer failing standard chemoradiation.
  • : e15635 Background: Most squamous cell carcinomas of the anal canal (SCC) respond to chemoradiation, but effective therapy for locally-invasive(T4) or recurrent disease that fails standard chemoradiation and/or salvage abdominoperineal resection (APR) has not been clearly delineated.
  • Fifteen patients reported long-term complications (>grade3): bowel obstruction in 8 (1 requiring operation), perineal wound fistula/non-healing in 9, leg paresthesia in 5, hydronephrosis in 3.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962742.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Fakih MG, Pendyala L, Egorin MJ, Fetterly G, Espinoza-Delgado I, Ross M, Phelan J, Kramer Z, Yirinec B, Diasio R: A phase I clinical trial of vorinostat in combination with sFULV2 in patients with refractory solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):4083

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pre-clinical studies demonstrate that vorinostat down-regulates intra-tumor TS in a dose-dependent fashion and augments 5-FU antitumor activity in xenograft models.
  • METHODS: Vorinostat was escalated in a standard 3 x 3 design in combination with a fixed dose of 5-FU and LV (simplified de Gramont regimen, sFULV2).
  • 21 pts had colorectal cancer (CRC), 1 had gastric, 1 had esophageal, and 1 had anal cancer.
  • Cycle 1 grade 3/4 toxicities consisted of thrombocytopenia, GI bleeding, fatigue, and H&F in 2 pts at the 2000 mg DL and a non-DLT G3 diarrhea (lasted <24 hrs) in 1 pt at the 1700 mg DL.
  • 12/21 CRC pts had a confirmed SD (11) or PR (1).
  • An expanded MTD cohort is accruing to investigate 5-FU-vorinostat PK interaction and intra-tumor TS down-regulation. (This work was supported by a grant from CTEP and the ACS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961640.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Lobato LF, Stocchi L, da Luz Moreira A, Kalady M, Dietz D, Geisler D, Lavery I, Fazio V: Effect of downstaging without complete pathologic response after neoadjuvant treatment on cancer outcomes for cIII and cII rectal cancers. J Clin Oncol; 2009 May 20;27(15_suppl):4108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of downstaging without complete pathologic response after neoadjuvant treatment on cancer outcomes for cIII and cII rectal cancers.
  • : 4108 Background: Neoadjuvant chemoradiation followed by surgery is standard of care for locally advanced rectal cancer.
  • The aim of this study was to evaluate whether downstaging impacts prognosis in patients with cII vs. cIII rectal cancer.
  • METHODS: We identified from our colorectal cancer database 233 patients with primary cII and cIII rectal cancer staged by CT and ERUS/MRI who received 5FU-based chemoradiation followed by R0 surgery after a median interval of 7 weeks during 1997-2007.
  • Patients with cII vs. cIII stage were statistically comparable regarding demographics, chemoradiation regimen, interval to surgery after neoadjuvant treatment, tumor distance from anal verge, operations performed and follow-up.
  • With the exception of local recurrence rates, downstaging resulted in significantly improved cancer outcomes for cIII but not cII ( Table ).
  • CONCLUSIONS: Downstaging without pCR is a significant prognostic factor for patients with stage cIII rectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961176.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Hammad N, Philip PA, Shields AF, Heilbrun LK, Venkatramanamoorthy R, El-Rayes BF: A retrospective review of squamous cell carcinoma of the anal canal in HIV-positive and HIV-negative patients. J Clin Oncol; 2009 May 20;27(15_suppl):e15586

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective review of squamous cell carcinoma of the anal canal in HIV-positive and HIV-negative patients.
  • : e15586 Background: Human immunodeficiency virus (HIV) infected patients (pts) are at increased risk for squamous cell carcinoma of the anal canal (SCCAC) and the incidence of SCCAC has increased in the era of HAART (highly active antiretroviral therapy).
  • The aim of this study is to describe the outcome, tolerability, and overall survival (OS) in pts with and without HIV infection treated at Karmanos Cancer Institute, at Wayne State University from 1991 to 2007.
  • We collected data regarding HIV status, demographics (age, gender, race), stage at diagnosis, treatment, response to treatment, toxicity, and survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962344.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Stanley M: Prophylactic HPV vaccines. Drugs Today (Barc); 2007 Oct;43(10):737-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The HPV L1 VLP vaccines are immensely important developments in public health and the benefits that they promise are immense, offering the opportunity to prevent, in the long term, 80% of cervical cancers, 60% of vulval cancers and 80% of anal cancers in women.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17987226.001).
  • [ISSN] 1699-3993
  • [Journal-full-title] Drugs of today (Barcelona, Spain : 1998)
  • [ISO-abbreviation] Drugs Today
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  •  go-up   go-down


25. Bertani E, Chiappa A, Mazzarol G, Contino G, Lazzari R, Zampino MG, Viale G, Andreoni B: Aggressive treatment approach for cloacogenic carcinoma of the anorectum: report from a single cancer center. Dig Surg; 2010;27(4):297-301
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive treatment approach for cloacogenic carcinoma of the anorectum: report from a single cancer center.
  • BACKGROUND/AIMS: The prognosis of cloacogenic carcinoma of the anorectum has rarely been investigated, and its clinical behavior is supposed to be similar to common squamous anal cancers.
  • During the last 10 years, chemoradiation treatment (CRT) has been considered the standard of care for anal cancer.
  • METHODS: We retrospectively investigated the treatment of cloacogenic cancers treated within the framework of a multidisciplinary cancer center team during an 8-year period.
  • The medical records of 7 patients affected by cloacogenic carcinoma were analyzed.
  • Three patients presented distant metastases at the time of diagnosis.
  • CONCLUSIONS: Our data seem to suggest that the cloacogenic origin could present prognostic relevance within the wide spectrum of anal cancers.
  • [MeSH-major] Anus Neoplasms / pathology. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Anal Canal / surgery. Biopsy, Needle. Cancer Care Facilities. Chemotherapy, Adjuvant. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20689291.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


26. Palefsky JM, Rubin M: The epidemiology of anal human papillomavirus and related neoplasia. Obstet Gynecol Clin North Am; 2009 Mar;36(1):187-200
MedlinePlus Health Information. consumer health - Colonoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The epidemiology of anal human papillomavirus and related neoplasia.
  • The relationship between cervical cancer and human papillomavirus (HPV) is well known.
  • Like cervical cancer, anal cancer is preceded by a series of precancerous changes, raising the possibility that like cervical cancer, anal cancer can be prevented.
  • Further, given the known risk factors for anal cancer, prevention efforts could be targeted to high-risk groups, providing a unique example of a screening program targeted to high-risk individuals.
  • This article describes the epidemiology of anal HPV infection, anal intraepithelial neoplasia, and anal cancer among men and women, as well as current efforts to prevent anal cancers.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / epidemiology. Colonoscopy / methods. Human papillomavirus 11. Papillomavirus Infections / epidemiology. Sexually Transmitted Diseases, Viral / epidemiology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Incidence. Male. Risk Factors. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19344856.001).
  • [ISSN] 1558-0474
  • [Journal-full-title] Obstetrics and gynecology clinics of North America
  • [ISO-abbreviation] Obstet. Gynecol. Clin. North Am.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 085178; United States / NCI NIH HHS / CA / R01 CA 88739; United States / NCRR NIH HHS / RR / UL1 RR02413,1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 49
  •  go-up   go-down


27. von Knebel Doeberitz M, Reuschenbach M: [Human papillomaviruses in the pathogenesis of intraepithelial neoplasia (AIN) and carcinoma of the anus]. Hautarzt; 2010 Jan;61(1):13-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Human papillomaviruses in the pathogenesis of intraepithelial neoplasia (AIN) and carcinoma of the anus].
  • [Transliterated title] Humane Papillomviren in der Pathogenese der intraepithelialen Neoplasien (AIN) und Karzinome des Anus.
  • HPV infections have been implicated in the pathogenesis of anal cancers.
  • The mode of infection and subsequent transformation resembles very much the pathogenesis of cervical and other HPV-associated cancers.
  • The molecular dissection of individual steps required to achieve cellular transformation within an HPV-infected cell led to the identification of novel biomarkers that make it possible to identify HPV-transformed cells with substantially higher precision in comparison to conventional methods.
  • Since effective antiretroviral therapy allows for possible long-term survival of HIV-infected individuals who are at very high risk to develop HPV-associated cancers in the anogenital tract, these new developments have become increasingly relevant for practicing dermatologists and proctologists.
  • [MeSH-major] Anus Neoplasms / virology. Biomarkers, Tumor / analysis. Carcinoma in Situ / physiopathology. Papillomavirus Infections / diagnosis. Papillomavirus Infections / virology. Precancerous Conditions / virology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20033115.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


28. Oon SF, Winter DC: Perianal condylomas, anal squamous intraepithelial neoplasms and screening: a review of the literature. J Med Screen; 2010;17(1):44-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perianal condylomas, anal squamous intraepithelial neoplasms and screening: a review of the literature.
  • Anal squamous intraepithelial lesions (ASILs) are the precursors to anal cancer.
  • Human papillomavirus infection has a direct link to ASIL formation and is responsible for up to 80% of anal cancers.
  • But while much importance has been focused on targeting cancer precursors in the cervix, relatively little concern has been afforded to the anal canal.
  • With the advent of cervical Pap smear screening in various regions, the incidence of cervical cancer has declined.
  • However, marked similarities in the biological and pathological profiles of cervical cancer and anal cancer mean that anal cancer should be preventable in the same way - by curbing the progression of ASIL to cancer.
  • This article explores the literature on ASILs and the growing problem of anal cancer in the community, along with the literature surrounding the current progress towards implementing a screening programme for ASIL in the future.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Condylomata Acuminata / diagnosis. Papillomavirus Infections / complications. Uterine Cervical Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Genital Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20356945.001).
  • [ISSN] 1475-5793
  • [Journal-full-title] Journal of medical screening
  • [ISO-abbreviation] J Med Screen
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 58
  •  go-up   go-down


29. Bockbrader M, Kim E: Role of intensity-modulated radiation therapy in gastrointestinal cancer. Expert Rev Anticancer Ther; 2009 May;9(5):637-47

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of intensity-modulated radiation therapy in gastrointestinal cancer.
  • Early clinical experience with IMRT in the treatment of gastric, pancreatic, rectal and anal cancers corroborates the dosimetric analyses, with some series reporting lower normal tissue toxicities.
  • This article reviews the radiobiological, physical, technical and clinical aspects of IMRT for gastric, pancreatic, rectal and anal cancer, and summarizes the dosimetric and outcome studies to date.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19445580.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 44
  •  go-up   go-down


30. Allison RR, Sheng C, Cuenca R, Bagnato VS, Austerlitz C, Sibata CH: Photodynamic therapy for anal cancer. Photodiagnosis Photodyn Ther; 2010 Jun;7(2):115-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for anal cancer.
  • Invasive anal cancers are generally successfully treated by combined chemotherapy with radiation therapy (XRT).
  • We examined the treatment and outcome of Photofrin based photodynamic therapy (PDT) in a cohort of patients with anal cancer who failed locally despite chemo-radiation (N=6) and two patients with positive margins of resection after excision of small T(1) squamous cell anal cancers who refused further surgery or chemo-radiation.
  • Red light (630 nm) illumination was delivered by a 5 cm diffusing fiber, treating transphincterally at 300 J/cm followed by microlens illumination at 200 J/cm(2) to the perianal tumor bed with 2 cm margin.
  • All patients completed PDT without incident and all have maintained local control of disease in the anal region for the length of follow up (18-48 months).
  • [MeSH-major] Anus Neoplasms / radiotherapy. Dihematoporphyrin Ether / therapeutic use. Photochemotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20510306.001).
  • [ISSN] 1873-1597
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 97067-70-4 / Dihematoporphyrin Ether
  • [Number-of-references] 22
  •  go-up   go-down


31. Berton F, Gola G, Wilson SR: Perspective on the role of transrectal and transvaginal sonography of tumors of the rectum and anal canal. AJR Am J Roentgenol; 2008 Jun;190(6):1495-504
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perspective on the role of transrectal and transvaginal sonography of tumors of the rectum and anal canal.
  • Our purpose is to describe the current status of sonography in the evaluation of rectal and anal tumors and in the staging of rectal cancer.
  • They are considered the reference standard for the preoperative staging of rectal and anal cancers and have relatively high accuracy in categorization of tumors and nodes in TNM staging.
  • [MeSH-major] Anus Neoplasms / ultrasonography. Image Enhancement / methods. Rectal Neoplasms / ultrasonography. Rectum / ultrasonography. Vagina / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18492898.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 53
  •  go-up   go-down


32. Walker F, Abramowitz L, Benabderrahmane D, Duval X, Descatoire V, Hénin D, Lehy T, Aparicio T: Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus. Hum Pathol; 2009 Nov;40(11):1517-27
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus.
  • High prevalence of squamous anal lesions is linked to oncogenic human papillomavirus (HPV).
  • Human immunodeficiency virus (HIV) promotes anal carcinogenesis.
  • Epidermal growth factor receptor (EGFR), HER2/neu, c-Met, and vascular endothelial growth factor receptor-1 (VEGFR1) (tyrosine kinase growth factor receptors) are implicated in tumor progression, but little is known about their role in anal lesions.
  • We investigated their expression and distribution in normal, dysplastic, and carcinomatous anal epithelium and then tried to analyze the effects on these variables of HPV and the HIV-positive status.
  • We studied growth factor receptors, p16 and Ki67 expression, by in situ hybridization, fluorescent in situ hybridization (FISH) and chromogen in situ hybridization (CISH), immunocytochemistry, and morphological quantification in 226 lesions, either infected by HPV6 and 11 (31 condylomas acuminata) or infected with oncogenic HPVs (48 invasive cancers, 147 anal intraepithelial neoplasias).
  • The number and intensity of EGFR- and c-Met-immunoreactive cells increased significantly during lesion progression, highlighting the effects of oncogenic HPvs. EGFR, c-Met, VEGFR1, and p16 were coexpressed in 96% of invasive cancers.
  • HIV-modified c-Met expression in condyloma acuminata (P < .008) and invasive cancers (P < .02).
  • HIV-positive anal cancers showed correlated c-Met and VEGFR1 (P < .003), strong p16 labeling, and an increased Ki67 proliferation.
  • The finding that EGFR, c-Met, and VEGFR1 involved in carcinogenesis are well-represented and coexpressed in anal cancers, especially in HIV-positive population, suggests possible novel targeted treatments for anal diseases.
  • [MeSH-major] Anus Neoplasms / genetics. Anus Neoplasms / virology. Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / virology. Receptors, Growth Factor / biosynthesis


33. Swampillai A, Williams M, Osborne M, Mawdsley S, Hughes R, Harrison M, Glynne-Jones R: A single-center study of the utility of squamous cell carcinoma antigen (SCCAg) levels in epidermoid carcinoma of the anal canal and margin (ECACM) treated with chemoradiation (CRT). J Clin Oncol; 2009 May 20;27(15_suppl):4117

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single-center study of the utility of squamous cell carcinoma antigen (SCCAg) levels in epidermoid carcinoma of the anal canal and margin (ECACM) treated with chemoradiation (CRT).
  • : 4117 Background: SCCAg is a tumour marker expressed by ECACM, measured by microparticle enzyme immunoassay; normal range 0-150ng/dl.
  • Radiotherapy comprised the schedule of the UK Anal cancer Trial (ACT II).
  • 30 had neo-adjuvant chemotherapy followed by CRT and 3 pts had planned surgery followed by CRT.
  • Clinical stage at diagnosis- Tx (6) T1 (28), T2 (80), T3 (65), T4 (16), N0 (126), N+ (66) Nx (3).
  • The mean baseline SCCAg for pts achieving CR was 408 and non CR was 513 (p = 0.13).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961219.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. de Parades V, Etienney I, Bauer P, Bourguignon J, Meary N, Mory B, Sultan S, Taouk M, Thomas C, Atienza P: Formalin application in the treatment of chronic radiation-induced hemorrhagic proctitis--an effective but not risk-free procedure: a prospective study of 33 patients. Dis Colon Rectum; 2005 Aug;48(8):1535-41
Hazardous Substances Data Bank. FORMALDEHYDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 11 anal cancers (33 percent), 11 prostate cancers, 9 cervical or endometrial cancers, 1 bladder cancer, and 1 rectal cancer.
  • Six anal or rectal strictures occurred: 4 patients had been treated for anal cancer (36 percent) and 2 patients had been treated for other cancers (9 percent).
  • None of the strictures was malignant.
  • Anal incontinence worsened in 5 patients of the 11 who had been treated for anal cancer (45 percent) and occurred in 4 of the 22 other patients (18 percent).
  • This result may be related to the high proportion of anal cancers in the series.
  • In our opinion, therefore, formalin application should be reserved for severe hemorrhagic proctitis refractory to medical treatment and should be thoroughly discussed in cases of anorectal radiation-induced stricture, prior anal incontinence, or treated anal cancer.
  • [MeSH-minor] Aged. Aged, 80 and over. Anus Diseases / etiology. Anus Neoplasms / radiotherapy. Blood Transfusion. Constriction, Pathologic / etiology. Fecal Incontinence / etiology. Female. Humans. Male. Middle Aged. Prospective Studies. Rectal Neoplasms / radiotherapy. Retreatment. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Proctitis.
  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dis Colon Rectum. 2006 Apr;49(4):530-1; author reply 531-2 [16416079.001]
  • (PMID = 15933799.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemostatics; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


35. Silverberg MJ, Abrams DI: Do antiretrovirals reduce the risk of non-AIDS-defining malignancies? Curr Opin HIV AIDS; 2009 Jan;4(1):42-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do antiretrovirals reduce the risk of non-AIDS-defining malignancies?
  • PURPOSE OF REVIEW: There is an increasing burden of non-AIDS-defining malignancies (NADMs) in the antiretroviral therapy (ART) era.
  • RECENT FINDINGS: Recent studies have increasingly focused on individual ART use, CD4 T-cell counts, and the risk of NADMs.
  • Certain NADMs have been shown to have a reduced risk with ART use including liver, breast, colorectal, and lung cancers.
  • NADMs associated with immunosuppression included Hodgkin's lymphoma, oral/pharynx, lung, anal, and colorectal cancers.
  • Despite the potential protective effect of ART on some NADMs, recent studies evaluating calendar era trends have noted an increased risk of Hodgkin's lymphoma and anal cancer and no change in risk for lung cancer in the ART era.
  • However, a continued high risk in the ART era for certain cancers have been observed, including Hodgkin's lymphoma and anal cancers.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect Dis. 2007 Jul 15;196(2):304-12 [17570119.001]
  • [Cites] AIDS. 1997 Aug;11(10):1300-1 [9256954.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] AIDS. 1999 Oct 22;13(15):2105-11 [10546864.001]
  • [Cites] JAMA. 1999 Dec 15;282(23):2220-6 [10605973.001]
  • [Cites] AIDS. 1997 Nov;11(13):1653-5 [9365774.001]
  • [Cites] AIDS. 1998 May 7;12(7):F45-9 [9619797.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] Leuk Lymphoma. 2005 Feb;46(2):207-15 [15621803.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Sex Transm Dis. 2005 May;32(5):314-20 [15849533.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1505-11 [16104038.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1383-8 [16549832.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]
  • [Cites] Neoplasia. 2007 Apr;9(4):271-8 [17460771.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] AIDS. 2007 Sep 12;21(14):1957-63 [17721103.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):446-51 [17762569.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5183-94 [17785575.001]
  • [Cites] Eur J Cancer. 2007 Sep;43(14):2117-23 [17764927.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10920-8 [18006837.001]
  • [Cites] AIDS. 2008 Jan 11;22(2):301-6 [18097233.001]
  • [Cites] AIDS Res Hum Retroviruses. 2008 Feb;24(2):163-8 [18240964.001]
  • [Cites] AIDS. 2008 Feb 19;22(4):489-96 [18301061.001]
  • [Cites] Addiction. 2008 Apr;103(4):651-9 [18339110.001]
  • [Cites] AIDS. 2008 Apr 23;22(7):841-8 [18427202.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] J Clin Oncol. 2008 Jun 1;26(16):2699-706 [18509182.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):485-90 [18614916.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):339-54 [18650512.001]
  • [Cites] Br J Cancer. 2008 Sep 2;99(5):800-4 [18665172.001]
  • [Cites] Cancer Causes Control. 2008 Dec;19(10):1251-8 [18618279.001]
  • [Cites] Eur J Cancer. 1999 Dec;35(13):1809-15 [10673996.001]
  • [Cites] Lancet. 2000 Jul 22;356(9226):291-6 [11071184.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] J Natl Cancer Inst Monogr. 2001;(28):44-9 [11158206.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):753-7 [11745473.001]
  • [Cites] Nat Med. 2002 Mar;8(3):225-32 [11875492.001]
  • [Cites] Blood. 2002 May 15;99(10):3771-9 [11986235.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5230-5 [12234989.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 Dec 1;31(4):384-90 [12447008.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):371-5 [12556691.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Lancet Oncol. 2003 Sep;4(9):537-47 [12965274.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2644-54 [15197808.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):861-8 [15213571.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85 [15220706.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7426-31 [15492266.001]
  • [Cites] Clin Infect Dis. 2004 Nov 1;39(9):1380-4 [15494916.001]
  • [Cites] AIDS. 1997 Feb;11(2):261-2 [9030382.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • (PMID = 19339938.001).
  • [ISSN] 1746-6318
  • [Journal-full-title] Current opinion in HIV and AIDS
  • [ISO-abbreviation] Curr Opin HIV AIDS
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI068641; United States / NIAID NIH HHS / AI / K01 AI071725; United States / NIAID NIH HHS / AI / U01 AI068641; United States / NIAID NIH HHS / AI / U01 AI068641-03; United States / NIAID NIH HHS / AI / K01AI071725; United States / NIAID NIH HHS / AI / UM1 AI068641; United States / NIAID NIH HHS / AI / AI071725-02; United States / NIAID NIH HHS / AI / AI068641-03; United States / NIAID NIH HHS / AI / K01 AI071725-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / Biomarkers
  • [Other-IDs] NLM/ NIHMS94539; NLM/ PMC2698664
  •  go-up   go-down


36. Handisurya A, Schellenbacher C, Kirnbauer R: Diseases caused by human papillomaviruses (HPV). J Dtsch Dermatol Ges; 2009 May;7(5):453-66; quiz 466, 467

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human papillomaviruses (HPV) are non-enveloped tumor viruses with a double stranded DNA approximately 8 kilobases in length.
  • They infect the squamous epithelia of skin and mucosa and usually cause benign papillomas or warts.
  • Persistent infection with high-risk oncogenic HPV causes all cervical cancers, most anal cancers, and a subset of vulvar, vaginal, penile and oropharyngeal cancers.
  • In recent years cutaneous beta-HPV types have been associated with the pathogenesis of non-melanoma skin cancers.
  • [MeSH-major] Papillomavirus Infections / diagnosis. Papillomavirus Infections / therapy. Skin Diseases, Viral / diagnosis. Skin Diseases, Viral / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19302229.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 11
  •  go-up   go-down


37. Tytherleigh MG, Birtle AJ, Cohen CE, Glynne-Jones R, Livingstone J, Gilbert J: Combined surgery and chemoradiation as a treatment for the Buschke-Löwenstein tumour. Surgeon; 2006 Dec;4(6):378-83
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined surgery and chemoradiation as a treatment for the Buschke-Löwenstein tumour.
  • BACKGROUND: The Buschke-Löwenstein tumour (BLT) or giant condyloma acuminata is a rare disease which affects the anogenital region.
  • Although histologically benign, it behaves in a malignant fashion, infiltrating the surrounding tissues.
  • The morbidity and mortality from this tumour is high, as is the risk of recurrence following treatment.
  • It lies on the continuum between the benign condylomata acuminata and squamous cell carcinoma.
  • Chemoradiation remains the mainstay of treatment for anal cancers but has not been routinely employed in the management of the BLT without squamous cell carcinoma transformation.
  • [MeSH-minor] Abdominal Neoplasms / secondary. Abdominal Neoplasms / therapy. Adult. Anus Neoplasms / secondary. Anus Neoplasms / therapy. Carcinoma in Situ / pathology. Carcinoma in Situ / therapy. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Fatal Outcome. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Rectal Neoplasms / secondary. Rectal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17152203.001).
  • [ISSN] 1479-666X
  • [Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  • [ISO-abbreviation] Surgeon
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


38. Monsonego J: [Anal cancer and human papillomaviruses: a perspective based on the cervical cancer model]. Gynecol Obstet Fertil; 2010 Apr;38(4):250-4
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal cancer and human papillomaviruses: a perspective based on the cervical cancer model].
  • [Transliterated title] Cancer anal et papillomavirus humains: une pathologie en miroir de celle du cancer du col utérin.
  • Anal cancer is a rare pathology in the general population but the incidence of this cancer has been on the rise for certain high-risk groups, such as homosexual men and immunodepressed subjects.
  • The incidence of anal cancer is 10 times higher in the HIV-positive population than in the female population in general.
  • Moderate to severe dysplasias (AIN2-3) are types of precancerous lesions that usually precede the appearance of the cancer.
  • In anal cancer, HPV16 is present in over 75% of the cases.
  • The prevalence of HPV in anal cancer is higher in women (90%) than in men (75%).
  • Squamous cervical and anal cancers have strong similarities founded on the causal association to HPV, in particular HPV16.
  • Recent data indicate that anti-HPV vaccination has a significant potential in preventing HPV infections, precancerous lesions, and anal cancer in the general population as well as in the high-risk groups.
  • [MeSH-major] Anus Neoplasms / epidemiology. Anus Neoplasms / virology. Human papillomavirus 16. Human papillomavirus 18. Papillomavirus Infections / epidemiology. Precancerous Conditions / virology. Uterine Cervical Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20362481.001).
  • [ISSN] 1769-6682
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Number-of-references] 24
  •  go-up   go-down


39. Hoots BE, Palefsky JM, Pimenta JM, Smith JS: Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer; 2009 May 15;124(10):2375-83
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions.
  • A systematic review was conducted of HPV type distribution in anal cancer and anal high-grade and low-grade squamous intraepithelial lesions (HSIL and LSIL).
  • A total of 1,824 cases were included: 992 invasive anal cancers, 472 HSIL cases and 360 LSIL cases.
  • Crude HPV prevalence in anal cancer, HSIL, and LSIL was 71, 91 and 88%, respectively.
  • HPV16/18 prevalence was 72% in invasive anal cancer, 69% in HSIL and 27% in LSIL.
  • The HPV 16 and/or 18 prevalence in invasive anal cancer cases was similar to that reported in invasive cervical cancer.
  • If ongoing clinical trials show efficacy in preventing anal HPV infection and associated anal lesions, prophylactic HPV vaccines may play an important role for the primary prevention of these cancers in both genders.
  • [MeSH-major] Anus Neoplasms / virology. Carcinoma in Situ / virology. Papillomaviridae / isolation & purification
  • [MeSH-minor] DNA, Viral / genetics. Female. Humans. Male. Neoplasm Invasiveness. Species Specificity

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 19189402.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Number-of-references] 26
  •  go-up   go-down


40. Goldberg RM, Niedzwiecki D, Bertagnolli M, Blackstock AW, Tepper JE, Mayer RJ: Cancer and leukemia group B gastrointestinal cancer committee. Clin Cancer Res; 2006 Jun 1;12(11 Pt 2):3589s-95s
Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827852291 for PMID:16740790 [PharmGKB] .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer and leukemia group B gastrointestinal cancer committee.
  • The Cancer and Leukemia Group B Gastrointestinal Cancer Committee was organized in the late 1970s under the leadership of Michael Perry and Philip Schein and began full-scale operations in the mid-1980s.
  • The Committee has done trials in patients with esophageal, gastric, pancreatic, colon, rectal, and anal cancers.
  • New initiatives are under way in hepatocellular cancer, cholangiocarcinoma, and neuroendocrine tumors originating in the gastrointestinal tract.
  • The Committee has increasingly concentrated on translational studies using tumor blocks, germ-line DNA, and plasma to evaluate biological correlates of tumor response and clinical outcomes.
  • Future efforts aim to evolve new standards of care, evaluate new therapies, and answer relevant biological questions in gastrointestinal cancer.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740790.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 43
  •  go-up   go-down


41. Steenbergen RD, de Wilde J, Wilting SM, Brink AA, Snijders PJ, Meijer CJ: HPV-mediated transformation of the anogenital tract. J Clin Virol; 2005 Mar;32 Suppl 1:S25-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infection with high-risk human papillomavirus (HR-HPV) has been associated with intraepithelial neoplasia and carcinomas at various sites of the anogenital tract, including the cervix, vulva, vagina, penis and anus.
  • Although HR-HPV is a necessary cause for cervical cancer, the majority of anal cancers and a subset of cancers at other genital sites, additional (epi)genetic events are required for malignant transformation.
  • Interference of E6 and E7 with cell cycle regulators induces genetic instability, which drives the continuous selection of oncogenic alterations providing cells with a malignant phenotype.
  • Early genetic events during cervical carcinogenesis associated with immortalization, include deletions at chromosomes 3p, 6 and 10p, whereas amongst others gain of chromosome 3q, loss of chromosome 11 and epigenetic alterations such as inactivation of the TSLC1 tumor suppressor gene represent later events associated with tumor invasion.
  • [MeSH-major] Anus Neoplasms / virology. Carcinoma in Situ / virology. Cell Transformation, Neoplastic. Papillomaviridae / physiology. Papillomavirus Infections / complications. Urogenital Neoplasms / virology
  • [MeSH-minor] Anal Canal / virology. Cell Cycle / genetics. Female. Genitalia / virology. Humans. Oncogene Proteins, Viral / physiology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15753009.001).
  • [ISSN] 1386-6532
  • [Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • [ISO-abbreviation] J. Clin. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Oncogene Proteins, Viral
  • [Number-of-references] 85
  •  go-up   go-down


42. Phan LK, Hoff PM: Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case. Dis Colon Rectum; 2007 Mar;50(3):395-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case.
  • Because of the high cure rate of localized anal cancers from combined modality treatment, there is little that is known for the treatment of patients who progress to have metastatic disease.
  • Treatments currently used are based on activity demonstrated in other cancers with similar histology.
  • Cetuximab, a molecular-targeted therapy, is an antibody directed against epidermal growth factor receptor that has demonstrated anticancer activity in several cancers.
  • We report a female patient with refractory anal cancer who achieved an excellent response to the combination of cetuximab and irinotecan after having failed single-agent irinotecan.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Carcinoma, Squamous Cell / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17252287.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 7673326042 / irinotecan; PQX0D8J21J / Cetuximab; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


43. Lee J, Corman M: Recurrence of anal adenocarcinoma after local excision and adjuvant chemoradiation therapy: report of a case and review of the literature. J Gastrointest Surg; 2009 Jan;13(1):150-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of anal adenocarcinoma after local excision and adjuvant chemoradiation therapy: report of a case and review of the literature.
  • INTRODUCTION: Tumors arising from the anal canal are rare, comprising 1.5% of all gastrointestinal tumors in the USA.
  • The vast majority of these anal cancers are epidermoid (cloacogenic/basaloid and squamous cell carcinomas), while adenocarcinomas reportedly occur 5% to 19% of the time.
  • Because of its rarity, reports about anal adenocarcinoma are limited to small retrospective studies and case reports.
  • Moreover, no series has directly compared outcomes between patients undergoing the various available treatment options, making it difficult to determine the optimal treatment for this aggressive cancer.
  • Current management of this cancer remains controversial, with some authors believing abdominoperineal resection with permanent colostomy should be considered the standard treatment.
  • CASE PRESENTATION: We describe a case of recurrent anal adenocarcinoma after conservative management with local excision and adjuvant chemoradiation therapy.
  • [MeSH-major] Adenocarcinoma / surgery. Antineoplastic Agents / therapeutic use. Anus Neoplasms / pathology. Anus Neoplasms / therapy. Colectomy / methods
  • [MeSH-minor] Adult. Biopsy. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18810561.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


44. Joseph DA, Miller JW, Wu X, Chen VW, Morris CR, Goodman MT, Villalon-Gomez JM, Williams MA, Cress RD: Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer; 2008 Nov 15;113(10 Suppl):2892-900
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Understanding the burden of human papillomavirus-associated anal cancers in the US.
  • BACKGROUND: Anal cancer is an uncommon malignancy in the US; up to 93% of anal cancers are associated with human papillomavirus.
  • METHODS: Cases diagnosed between 1998 and 2003 from 39 population-based cancer registries were analyzed.
  • The following anal cancer histologies were included in the analysis: squamous cell, adenocarcinoma, and small cell/neuroendocrine carcinomas.
  • RESULTS: From 1998 through 2003, the annual age-adjusted invasive anal cancer incidence rate was 1.5 per 100,000 persons.
  • Squamous cell carcinoma (SCC) was the most common histology overall, accounting for 18,105 of 21,395 (84.6%) cases of anal cancer.
  • Incidence rates of anal SCC increased 2.6% per year on average.
  • CONCLUSIONS: Rates of anal SCC varied by sex, race, and ethnicity.
  • Continued surveillance and additional research are needed to assess the potential impact of the HPV vaccine on the anal cancer burden in the US.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1464-9 [10717631.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):311-20 [12556684.001]
  • [Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1517-23; discussion 1523-4; author reply 1524 [14605572.001]
  • [Cites] Cancer Causes Control. 2003 Nov;14(9):837-46 [14682441.001]
  • [Cites] Lancet Oncol. 2004 Mar;5(3):149-57 [15003197.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] Gastroenterology. 1988 Jul;95(1):107-11 [2836255.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):180-9 [1311142.001]
  • [Cites] Am J Epidemiol. 1992 Jul 1;136(1):54-8 [1329500.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] Am J Epidemiol. 1994 Jul 1;140(1):12-9 [8017399.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Semin Cancer Biol. 1998 Aug;8(4):307-13 [9870037.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):753-7 [9973228.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2006 Oct 27;55(42):1145-8 [17065979.001]
  • [Cites] Stat Methods Med Res. 2006 Dec;15(6):547-69 [17260923.001]
  • [Cites] Lancet Oncol. 2007 Apr;8(4):311-6 [17395104.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):919-25 [17527081.001]
  • [Cites] Clin Microbiol Rev. 2007 Jul;20(3):478-88, table of contents [17630336.001]
  • [Cites] Sex Transm Infect. 2007 Jul;83(4):257-66 [17664359.001]
  • [Cites] Cancer Causes Control. 2007 Dec;18(10):1175-86 [17805982.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2841-54 [18980203.001]
  • [Cites] Dermatol Ther. 2005 Jan-Feb;18(1):67-76 [15842614.001]
  • [Cites] Dan Med Bull. 2002 Aug;49(3):194-209 [12238281.001]
  • (PMID = 18980293.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] None / None / / N01 PC035137; United States / NCCDPHP CDC HHS / DP / U50 DP424071; United States / NCI NIH HHS / PC / N01 PC035137; United States / NCCDPHP CDC HHS / DP / U50 DP424071-04
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS104103; NLM/ PMC2729501
  •  go-up   go-down


45. Lukan N, Ströbel P, Willer A, Kripp M, Dinter D, Mai S, Hochhaus A, Hofheinz RD: Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology; 2009;77(5):293-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status.
  • BACKGROUND: No standard chemotherapy regimen can be defined for patients with metastatic squamous cell carcinoma of the anus due to the low incidence of this disease and the high cure rate of localized tumors.
  • Anal cancers universally express the epidermal growth factor receptor (EGFR) and KRAS mutations have not been reported in anal cancer thus far.
  • METHODS: We report on 7 patients with metastatic anal cancer treated with cetuximab - a chimeric antibody against EGFR - on a compassionate use basis along with the results of KRAS mutational analysis.
  • RESULTS: Marked tumor shrinkage was noted in several patients using cetuximab monotherapy or cetuximab/irinotecan combination as first or subsequent treatment line (usually after failure of cisplatin-based regimens).
  • Both patients had progressive disease receiving cetuximab, while the remaining 5 patients had either a partial remission (n = 3), a minor remission (n = 1) or no change lasting > or =6 months after previous rapid tumor progression.
  • CONCLUSION: Cetuximab-based treatment appears to be a valuable treatment option for patients with metastatic KRAS wild-type anal cancer after failure of or as an alternative to cisplatin/5-fluorouracil-based therapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Mutation. Proto-Oncogene Proteins / genetics. Receptor, Epidermal Growth Factor / antagonists & inhibitors. ras Proteins / genetics

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19923868.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins; PQX0D8J21J / Cetuximab
  •  go-up   go-down


46. Kreuter A, Potthoff A, Brockmeyer NH, Gambichler T, Swoboda J, Stücker M, Schmitt M, Pfister H, Wieland U, German Competence Network HIV/AIDS: Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany. Br J Dermatol; 2010 Jun;162(6):1269-77
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany.
  • BACKGROUND: Anal intraepithelial neoplasia (AIN), a human papillomavirus (HPV)-associated potential precursor lesion of anal cancer, is frequent among human immunodeficiency virus (HIV)-positive men who have sex with men (MSM).
  • There is a paucity of data published on the progression of high-grade AIN to invasive cancer as well as on clinical and virological characteristics comparing anal margin and anal canal carcinoma.
  • OBJECTIVES: To search for anal carcinoma and AIN in a large series of HIV-positive MSM, to assess treatment response of anal carcinoma, and to analyse lesional HPV spectrum of anal cancers.
  • METHODS: Detection of anal carcinoma and AIN was performed using cytology, high-resolution anoscopy, and histology in case of abnormal findings.
  • Additionally, HPV analyses for 36 high- and low-risk α-HPV types were performed in patients with anal carcinoma.
  • Of these, 116 (26·0%) patients had normal findings, 163 (36·5%) had low-grade AIN, 156 (35·0%) had high-grade AIN, and 11 (2·5%) had anal carcinoma as evidenced by the highest grade of cytology/histology.
  • Five patients with anal cancer, who had refused treatment of their precancerous lesions, had progressed from high-grade AIN to invasive cancer within a median time of 8·6 months.
  • All anal cancers carried high-risk α-HPV types.
  • All five squamous cell carcinomas (SCCs) of the anal canal were HPV16 positive.
  • In contrast, only one of the four anal margin SCCs were HPV16 positive (HPV31, HPV33 and HPV33 + HPV68 were found in the other three anal margin SCCs).
  • In contrast to the cancer biopsies, a broad spectrum of surface high- and low-risk HPV types was found in anal swabs of the patients.
  • Surgical excision resulted in long-term disease control of all anal margin carcinomas, whereas combined chemoradiotherapy in carcinomas of the anal canal was associated with high recurrence rates, high toxicity, and high mortality.
  • CONCLUSIONS: Anal carcinoma and AIN are frequent in HIV-positive men, even in patients participating in anal cancer prevention programmes.
  • High-grade dysplasia in these patients can progress to invasive cancer within a short period of time.
  • Anal margin carcinoma and anal canal carcinoma differ substantially in their lesional HPV spectrum, prognosis and treatment response.
  • [MeSH-major] Anus Neoplasms / virology. Carcinoma in Situ / virology. Carcinoma, Squamous Cell / virology. HIV Seropositivity / complications. Papillomaviridae / isolation & purification

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal Compilation © 2010 British Association of Dermatologists.
  • (PMID = 20184584.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00365729
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


47. Hatzaras I, Abir F, Kozol R, Sullivan P, Longo WE: The demographics, histopathology and patterns of treatment of anal cancer in Connecticut: 1980-2000. Conn Med; 2005 May;69(5):261-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The demographics, histopathology and patterns of treatment of anal cancer in Connecticut: 1980-2000.
  • OBJECTIVES: Examine the epidemiology and clinical characteristics of anal cancer in the State of Connecticut.
  • MATERIALS AND METHODS: The Department of Health Connecticut Tumor Registry resources were utilized for the years 1980-2000.
  • RESULTS: A total of 646 anal cancers (410 females, 236 males) were diagnosed (mean age: 63.4 years).
  • The most prominent histological type was squamous cell carcinoma, followed by adenocarcinoma and cloacogenic carcinoma.
  • CONCLUSIONS: Anal cancer incidence in Connecticut increased in the 21-year period 1980 to 2000, affecting the rate for African-American men more than other race-specific and gender-specific population subgroups.
  • Anal cancer affects women more often than men.
  • Squamous cell carcinoma is the most common histological type.
  • [MeSH-major] Adenocarcinoma / epidemiology. Anus Neoplasms / epidemiology. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / epidemiology
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Colectomy / methods. Combined Modality Therapy. Connecticut / epidemiology. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Registries. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Analysis

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16114640.001).
  • [ISSN] 0010-6178
  • [Journal-full-title] Connecticut medicine
  • [ISO-abbreviation] Conn Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Liu H, Wu BH, Rowse GJ, Emtage PC: Induction of CD4-independent E7-specific CD8+ memory response by heat shock fusion protein. Clin Vaccine Immunol; 2007 Aug;14(8):1013-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infection with human papillomavirus type 16 (HPV16) is strongly associated with a number of disease states, of which cervical and anal cancers represent the most drastic endpoints.
  • Induction of T-cell-mediated immunity, particularly cytotoxic T lymphocytes (CTL), is important in eradication of HPV-induced lesions.
  • These CD8(+) T cells can differentiate into memory T cells with effector functions in the absence of CD4(+) T-cell help.
  • The HspE7-induced memory CD8(+) T cells persist for at least 17 weeks and confer protection against E7-positive murine tumor cell challenge.
  • Moreover, the ability of HspE7 to induce memory CD8(+) T cells in the absence of CD4(+) help indicates that HspE7 fusion protein may have activity in individuals with compromised CD4(+) functions, such as those with invasive cancer and/or human immunodeficiency virus infection.
  • [MeSH-minor] Animals. Antineoplastic Agents. Cell Line, Tumor. Chaperonin 60. Cytokines / metabolism. Female. Human papillomavirus 16 / immunology. Humans. Immunization. Mice. Mice, Inbred C57BL. Papillomavirus E7 Proteins. Papillomavirus Infections / prevention & control. T-Lymphocytes, Cytotoxic / immunology. Tumor Virus Infections / prevention & control

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 2000 Jan 17;191(2):403-8 [10637285.001]
  • [Cites] Immunol Rev. 2006 Jun;211:146-53 [16824124.001]
  • [Cites] Clin Exp Immunol. 2000 Aug;121(2):216-25 [10931134.001]
  • [Cites] Nat Immunol. 2000 Jul;1(1):47-53 [10881174.001]
  • [Cites] Nat Rev Immunol. 2002 Apr;2(4):251-62 [12001996.001]
  • [Cites] Eur J Immunol. 2002 Aug;32(8):2199-207 [12209632.001]
  • [Cites] J Immunol. 2002 Sep 15;169(6):2875-85 [12218100.001]
  • [Cites] Science. 2002 Sep 20;297(5589):2060-3 [12242444.001]
  • [Cites] J Immunol. 2002 Oct 1;169(7):3760-70 [12244170.001]
  • [Cites] J Immunol. 2002 Nov 15;169(10):5622-9 [12421941.001]
  • [Cites] Cell. 2002 Dec 13;111(6):837-51 [12526810.001]
  • [Cites] Vaccine. 2003 Feb 14;21(9-10):897-901 [12547600.001]
  • [Cites] Nature. 2003 Feb 20;421(6925):852-6 [12594515.001]
  • [Cites] Nat Immunol. 2003 Mar;4(3):225-34 [12563257.001]
  • [Cites] Science. 2003 Apr 11;300(5617):337-9 [12690201.001]
  • [Cites] Science. 2003 Apr 11;300(5617):339-42 [12690202.001]
  • [Cites] J Immunol. 2003 May 15;170(10):4933-42 [12734336.001]
  • [Cites] Lancet. 2003 Aug 9;362(9382):469-76 [12927437.001]
  • [Cites] Crit Rev Oral Biol Med. 2003;14(5):345-62 [14530303.001]
  • [Cites] Eur J Immunol. 2003 Dec;33(12):3225-31 [14635030.001]
  • [Cites] J Immunol. 2003 Dec 15;171(12):6339-43 [14662830.001]
  • [Cites] Immunity. 2003 Dec;19(6):823-35 [14670300.001]
  • [Cites] Nat Rev Immunol. 2004 Jan;4(1):46-54 [14704767.001]
  • [Cites] Int J Cancer. 2004 Mar 1;108(6):857-62 [14712488.001]
  • [Cites] J Immunol. 2004 Mar 1;172(5):2885-93 [14978090.001]
  • [Cites] Annu Rev Immunol. 2004;22:711-43 [15032594.001]
  • [Cites] Curr Opin Immunol. 2004 Jun;16(3):259-63 [15134772.001]
  • [Cites] Nat Immunol. 2004 Sep;5(9):927-33 [15300249.001]
  • [Cites] Cancer Res. 1986 Aug;46(8):4109-15 [3731078.001]
  • [Cites] Virology. 1991 Sep;184(1):9-13 [1651607.001]
  • [Cites] Eur J Immunol. 1993 Sep;23(9):2242-9 [7690326.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):21-6 [8548765.001]
  • [Cites] Science. 1996 Apr 5;272(5258):54-60 [8600537.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4855-61 [9354449.001]
  • [Cites] Biotherapy. 1998;10(3):173-89 [9559972.001]
  • [Cites] Vaccine. 1999 Jan 28;17(4):373-83 [9987177.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8761-6 [15574788.001]
  • [Cites] Gynecol Oncol. 2005 Jan;96(1):92-102 [15589586.001]
  • [Cites] Clin Obstet Gynecol. 2005 Mar;48(1):226-40 [15725875.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):2018-25 [15753402.001]
  • [Cites] J Clin Virol. 2005 Mar;32 Suppl 1:S72-81 [15753015.001]
  • [Cites] Nat Med. 2005 Jul;11(7):748-56 [15951824.001]
  • [Cites] Br J Cancer. 2005 Jul 25;93(2):248-59 [15986031.001]
  • [Cites] Oncologist. 2005 Aug;10(7):528-38 [16079320.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2005 Aug;19(4):531-44 [16150392.001]
  • [Cites] Ann N Y Acad Sci. 2005 Nov;1056:328-43 [16387699.001]
  • [Cites] Eur J Immunol. 2006 May;36(5):1324-36 [16619287.001]
  • [Cites] Gynecol Oncol. 2006 Jul;102(1):22-31 [16427684.001]
  • [Cites] Immunol Rev. 2006 Jun;211:67-80 [16824118.001]
  • [Cites] Immunity. 2000 Mar;12(3):263-72 [10755613.001]
  • (PMID = 17596433.001).
  • [ISSN] 1556-6811
  • [Journal-full-title] Clinical and vaccine immunology : CVI
  • [ISO-abbreviation] Clin. Vaccine Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Antineoplastic Agents; 0 / Bacterial Proteins; 0 / Chaperonin 60; 0 / Cytokines; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / Papillomavirus Vaccines; 0 / Recombinant Fusion Proteins; 0 / heat-shock protein 65, Mycobacterium; 0 / oncogene protein E7, Human papillomavirus type 16; EC 3.6.1.- / Chaperonins
  • [Other-IDs] NLM/ PMC2044492
  •  go-up   go-down


49. Dandapani SV, Eaton M, Thomas CR Jr, Pagnini PG: HIV- positive anal cancer: an update for the clinician. J Gastrointest Oncol; 2010 Sep;1(1):34-44
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV- positive anal cancer: an update for the clinician.
  • Anal cancer used to be a rare cancer traditionally associated with elderly women.
  • The onslaught of the Human Immunodeficiency Virus (HIV) virus has led to a change in anal cancer demographics.
  • Anal cancer is on the rise in the U.S and the number of anal cases documented has quadrupled in the past 20 yrs correlating with the rise of the HIV epidemic.
  • The incidence of anal cancer is 40 to 80 fold higher in the HIV positive (HIV+) population when compared to the general population (2).
  • As a consequence non AIDS defining cancers such as anal cancer are on the rise.
  • Factors implicated in the etiology of anal cancer in HIV+ patients include (Human papillomavirus) HPV virus status, sexual habits, and a history of smoking.
  • HPV 16 and receptive anal intercourse (RAI) increase the risk of anal cancer by 33% over the general population.
  • In the general population, the rate of anal cancer is approximately 0.9 cases per 100,000.
  • In patients with a history of RAI, the rate approaches 35 cases per 100,000 which is equivalent to the prevalence of cervical cancer (3).
  • Smokers are eight times more likely to develop anal cancer.
  • There has been much discussion about tailoring treatment decisions in HIV+ patients with anal cancer.
  • This review focuses on squamous cell carcinomas of the anal canal which comprise 80 to 90% of all anal cancers diagnosed and highlight key issues in the management of HIV+ anal cancer patients including recent clinical trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Med Assoc. 1992 Feb;84(2):165-76 [1602515.001]
  • [Cites] Br J Dermatol. 2010 Jun;162(6):1269-77 [20184584.001]
  • [Cites] Dis Colon Rectum. 1994 Sep;37(9):861-5 [8076484.001]
  • [Cites] J Infect Dis. 2004 Nov 1;190(9):1685-91 [15478076.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1176-81 [15906137.001]
  • [Cites] Oncology (Williston Park). 2005 Nov;19(12):1634-8; discussion 1638-40, 1645 passim [16396154.001]
  • [Cites] Radiat Oncol. 2006;1:29 [16916475.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4581-6 [17925552.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):2-9 [18030528.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):73-81 [18066626.001]
  • [Cites] Dis Colon Rectum. 2008 Feb;51(2):147-53 [18180997.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2550-7 [18427149.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] J Clin Oncol. 2008 Jun 1;26(16):2699-706 [18509182.001]
  • [Cites] Curr Opin Oncol. 2008 Sep;20(5):534-40 [19106656.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):143-9 [19203845.001]
  • [Cites] Hum Pathol. 2009 Nov;40(11):1517-27 [19716155.001]
  • [Cites] Radiother Oncol. 2009 Nov;93(2):298-301 [19717198.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1425-32 [19744801.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):474-9 [19779306.001]
  • [Cites] Diagn Cytopathol. 2010 Jul;38(7):538-46 [19941374.001]
  • [Cites] Sex Transm Dis. 2010 May;37(5):311-5 [20065890.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1413-9 [20231064.001]
  • [Cites] Br J Cancer. 2010 Mar 30;102(7):1123-8 [20354531.001]
  • [Cites] AIDS. 2010 Apr 24;24(7):1085-6; author reply 1086-7 [20386381.001]
  • [Cites] Hematol Oncol Clin North Am. 2010 Jun;24(3):567-75 [20488354.001]
  • [Cites] Oncology (Williston Park). 2010 Aug;24(9):828, 830-1 [20923036.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Cancer J Sci Am. 1996 Jul-Aug;2(4):205-11 [9166533.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5 [9169819.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 15;14(5):415-22 [9170415.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):651-7 [9336145.001]
  • [Cites] Dis Colon Rectum. 1998 Dec;41(12):1488-93 [9860327.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):127-31 [10219805.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] Dis Colon Rectum. 2001 May;44(5):690-8 [11357031.001]
  • [Cites] Dis Colon Rectum. 2001 Oct;44(10):1496-502 [11598480.001]
  • [Cites] Dis Colon Rectum. 2002 Apr;45(4):453-8 [12006924.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5230-5 [12234989.001]
  • [Cites] Oncology. 2003;65(1):14-22 [12837978.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):859-72 [12852659.001]
  • [Cites] Dis Colon Rectum. 2004 Aug;47(8):1305-9 [15484343.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):354-61 [16168830.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):206-11 [16904522.001]
  • [Cites] Dis Colon Rectum. 2009 May;52(5):891-7 [19502853.001]
  • [Cites] Lancet Oncol. 2009 Dec;10(12):1152-9 [19818686.001]
  • [Cites] Curr Probl Cancer. 2009 Sep-Oct;33(5):302-26 [20082844.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • (PMID = 22811803.001).
  • [ISSN] 2219-679X
  • [Journal-full-title] Journal of gastrointestinal oncology
  • [ISO-abbreviation] J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3397564
  • [Keywords] NOTNLM ; Anal canal / Anal cancer / HIV
  •  go-up   go-down


50. Barbaro G, Barbarini G: HIV infection and cancer in the era of highly active antiretroviral therapy (Review). Oncol Rep; 2007 May;17(5):1121-6
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV infection and cancer in the era of highly active antiretroviral therapy (Review).
  • The majority of cancers affecting HIV-infected subjects are those established as acquired immunodeficiency syndrome (AIDS)-defining: Kaposi's sarcoma (KS), non-Hodgkin's lymphoma (NHL), and invasive cervical cancer (ICC).
  • However, other types of cancer, such as Hodgkin's disease (HD), anal cancer, lung cancer and testicular germ cell tumors appear to be more common among HIV-infected subjects compared to the general population.
  • The mechanisms by which depressed immunity could increase the risk for cancer are unclear, except for in KS and most subtypes of NHL, where it is strictly associated with a low CD4 count.
  • Studies of the effect of highly active antiretroviral therapy (HAART) on the incidence and progression of HIV/AIDS-associated cancers provided contrasting data.
  • While a significant decrease in the incidence of KS has been observed, HAART has not had a significant impact on NHL incidence, particularly systemic NHL, or on ICC, HD, anal cancers and other non-AIDS-defining cancers.
  • Regardless of whether these cancers are directly related to HIV-induced immunodeficiency, treating cancer in HIV-infected patients remains a challenge because of drug interactions, compounded side effects, and the potential effect of chemotherapy on CD4 count and HIV-1 viral load.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17390054.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 44
  •  go-up   go-down


51. Iagaru A, Kundu R, Jadvar H, Nagle D: Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma. Hell J Nucl Med; 2009 Jan-Apr;12(1):26-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma.
  • Anal squamous cell carcinoma (ASCC) is a rare cancer of the gastrointestinal tract, representing less than 5% of the digestive malignancies.
  • Our results showed that PET demonstrated the primary lesion at initial evaluation in 7 of 8 anal cancers and showed FDG- avid lymph nodes in 4 patients.
  • [MeSH-major] Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19330178.001).
  • [ISSN] 1790-5427
  • [Journal-full-title] Hellenic journal of nuclear medicine
  • [ISO-abbreviation] Hell J Nucl Med
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


52. Abbas A, Yang G, Fakih M: Management of anal cancer in 2010. Part 1: Overview, screening, and diagnosis. Oncology (Williston Park); 2010 Apr 15;24(4):364-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of anal cancer in 2010. Part 1: Overview, screening, and diagnosis.
  • Although anal cancer is a rare disease, its incidence is increasing in men and women worldwide.
  • Anal cancer is generally preceded by high-grade anal intraepithelial neoplasia (HGAIN), which is most prevalent in human immunodeficiency virus (HIV)-positive men who have sex with men.
  • Meta-analysis suggests that 80% of anal cancers could be avoided by vaccination against HPV 16/18.
  • Nearly half of all patients with anal cancer present with rectal bleeding.
  • Pain or sensation of a rectal mass is experienced in 30% of patients, whereas 20% have no tumor-specific symptoms.
  • According to the Surveillance Epidemiology and End Results (SEER) database, 50% of patients with anal cancer have disease localized to the anus, 29% have regional lymph node involvement or direct spread beyond the primary, and 12% have metastatic disease, while 9% have an unknown stage.
  • Clinical staging of anal carcinoma requires a digital rectal exam and a computed tomography scan of the chest, abdomen, and pelvis.
  • The 5-year relative survival rates are 80.1% for localized anal cancer, 60.7% for regional disease, and 29.4% for metastatic disease.
  • Part 2 of this two-part review will address the treatment of anal cancer, highlighting studies of chemoradiation.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / prevention & control. Mass Screening

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20464850.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 94
  •  go-up   go-down


53. Karandikar SS, Borley A, Crosby T, Williams G, Reynolds S, Radcliffe AG: A five-year audit of anal cancer in Wales. Colorectal Dis; 2006 May;8(4):266-72
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A five-year audit of anal cancer in Wales.
  • OBJECTIVES: A retrospective audit has been undertaken of Squamous (epidermoid) type of anal cancer diagnosed and treated in the principality of Wales over a five-year period (1995-99) with follow-up until 2005.
  • METHODS: Patients were identified from the Welsh Cancer Registry and the pathology databases of the 17 acute hospitals in Wales.
  • Twenty-six anal cancers were diagnosed per year in the region.
  • CONCLUSIONS: This is a unique regional audit of anal cancer.
  • This study concurs that Human Papilloma Virus appears to predispose to Squamous anal cancer.
  • As recommended by NICE all patients should be referred to a multidisciplinary anal cancer team, which can provide individual treatment plans.
  • Increased specialization could mean specialist regional MDTs for anal cancer.
  • [MeSH-major] Anus Neoplasms / therapy. Neoplasms, Squamous Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Medical Audit. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome. Wales / epidemiology

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16630228.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


54. Huang K, Haas-Kogan D, Weinberg V, Krieg R: Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal. World J Gastroenterol; 2007 Feb 14;13(6):895-900
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal.
  • AIM: To assess whether radiation dose and duration of treatment influence local control and survival of patients with locally advanced anal cancer treated with definitive chemoradiation.
  • METHODS: Twenty-eight consecutive patients who were treated with definitive radiation therapy for bulky anal cancers (> 5 cm in size) were reviewed.
  • The median tumor size was 7.5 cm.
  • CONCLUSION: Local failure is a significant problem in locally advanced carcinomas of the anal canal.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2003 Jan;39(1):45-51 [12504657.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):354-61 [16168830.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):823-31 [12788191.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1153-60 [2599903.001]
  • [Cites] Radiother Oncol. 1993 Jun;27(3):209-15 [8210457.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jul 1;35(4):745-9 [8690640.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):313-24 [9069302.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2329-35 [9191520.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):675-80 [11395235.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):651-7 [9336145.001]
  • [Cites] Radiother Oncol. 1998 Mar;46(3):249-56 [9572617.001]
  • [Cites] Oncology. 1998 Nov-Dec;55(6):525-32 [9778618.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):127-31 [10219805.001]
  • [Cites] Cancer J Sci Am. 1996 Jul-Aug;2(4):205-11 [9166533.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1195-202 [12599225.001]
  • (PMID = 17352019.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC4065925
  •  go-up   go-down


55. Balamurugan A, Ahmed F, Saraiya M, Kosary C, Schwenn M, Cokkinides V, Flowers L, Pollack LA: Potential role of human papillomavirus in the development of subsequent primary in situ and invasive cancers among cervical cancer survivors. Cancer; 2008 Nov 15;113(10 Suppl):2919-25
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential role of human papillomavirus in the development of subsequent primary in situ and invasive cancers among cervical cancer survivors.
  • BACKGROUND: The recent licensure of human papillomavirus (HPV) vaccines will likely decrease the development of primary in situ and invasive cervical cancers and possibly other HPV-associated cancers such as vaginal, vulvar, and anal cancers.
  • Because the HPV vaccine has the ability to impact the development of >1 HPV-associated cancer in the same individual, the risk of developing subsequent primary cancers among cervical cancer survivors was examined.
  • METHODS: Using the 1992 through 2004 data from the Surveillance, Epidemiology, and End Results (SEER) program, 23,509 cervical cancer survivors were followed (mean of 4.8 person-years) for the development of subsequent primary cancers.
  • The observed number (O) of subsequent cancers of all sites were compared with those expected (E) based on age-/race-/year-/site-specific rates in the SEER population.
  • RESULTS: Among cervical cancer index cases, there was a significant elevated risk for subsequent in situ cancers of the vagina and vulva (SIRs of 53.8 and 6.6, respectively); and invasive vaginal, vulvar, and rectal cancers (SIRs of 29.9, 5.7, and 2.2, respectively).
  • Significantly elevated risks were observed across race and ethnic populations for subsequent vaginal in situ (SIR for whites of 49.4; blacks, 52.8; Asian/Pacific Islander [API], 91.4; and Hispanics, 55.7) and invasive cancers (SIR for whites of 25.7; blacks, 34.5; API, 48.5; and Hispanics, 25.2).
  • CONCLUSIONS: The results of the current study demonstrate a substantially increased risk of the development of subsequent primary in situ and invasive cancers among cervical cancer survivors and have implications for the development of prevention and early detection strategies as the role of HPV infection becomes evident.
  • [MeSH-major] Carcinoma in Situ / epidemiology. Carcinoma in Situ / virology. Neoplasms, Second Primary / epidemiology. Neoplasms, Second Primary / virology. Papillomavirus Infections / complications. Uterine Cervical Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Anus Neoplasms / epidemiology. Child. Continental Population Groups. Female. Humans. Middle Aged. Risk. SEER Program. Survivors. United States / epidemiology. United States / ethnology. Vaginal Neoplasms / epidemiology. Vaginal Neoplasms / virology. Vulvar Neoplasms / epidemiology. Vulvar Neoplasms / virology

  • Genetic Alliance. consumer health - Cervical cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18980275.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCCDPHP CDC HHS / DP / U50 DP424071-04
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


56. Echenique I, Cabanillas F, Texidor V, Cáceres J, Isenberg G, Claudio C, Ayala R, Madera F: A proposed approach for the selection of the proper surgical therapy to obtain an adequate margin of resection in locally advanced ultra-low rectal cancer after modern preoperative CRX management. Bol Asoc Med P R; 2009 Apr-Jun;101(2):53-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A proposed approach for the selection of the proper surgical therapy to obtain an adequate margin of resection in locally advanced ultra-low rectal cancer after modern preoperative CRX management.
  • OBJECTIVE: We performed a retrospective review to identify objective factors that could facilitate the surgeon's decision regarding the feasibility of an adequate resection with a margin of< 2 cm from the dentate line.
  • We proposed what state of the art imaging tools are potentially useful to identify tumor downstage following preoperative CRX and aid in the development of guidelines.
  • METHODS: Reviewed of the literature on the subject and performance of current diagnostic imaging studies useful in identifying rectal tumor downstaging after preoperative CRX.
  • All sphincter saving rectal cancer operations results for ultra-low tumors need to be as good as results from an APR.
  • Performing frozen section for the ultralow rectal cancer margins is recommended.
  • It could turn out to be an objective and accurate method of evaluating tumor downstaging.
  • Color Doppler evaluation has shown higher specificity than that of grey scale ultrasound in staging and differentiating scar from anal cancers.
  • CONCLUSION: At this point with the information available from the literature, we suggest that patients with clinically advanced rectal cancer can have a distal margin resection of less than 2 cm if: 1- the tumor is not mucin producing, 2- the tumor is not high-grade, and 3- the response to preop CRX is adequate, however there exist no clear guidelines available to judge what is an excellent versus a moderate or poor response.
  • [MeSH-major] Carcinoma / surgery. Digestive System Surgical Procedures / methods. Practice Guidelines as Topic. Rectal Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Diagnostic Imaging. Humans. Neoplasm Recurrence, Local / prevention & control. Retrospective Studies

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954103.001).
  • [ISSN] 0004-4849
  • [Journal-full-title] Boletín de la Asociación Médica de Puerto Rico
  • [ISO-abbreviation] Bol Asoc Med P R
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Puerto Rico
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 17
  •  go-up   go-down


57. Giuliano AR, Tortolero-Luna G, Ferrer E, Burchell AN, de Sanjose S, Kjaer SK, Muñoz N, Schiffman M, Bosch FX: Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine; 2008 Aug 19;26 Suppl 10:K17-28
MedlinePlus Health Information. consumer health - Genital Warts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions.
  • The association of HPV DNA with several different ano-genital cancers other than cervical has been reported for the vulva, vagina, anus and penis.
  • HPV DNA has also been identified in head and neck cancers in the oral cavity, the oropharynx and the larynx in both sexes.
  • In men, 80-85% of anal cancers and close to 50% of penile cancers are associated with HPV infection.
  • In women, HPV DNA is prevalent in 36-40% vulvar cancer cases and close to 90% of vaginal cancers.
  • Among HPV DNA positive ano-genital cancer cases, HPV-16 is the most frequently found followed distantly by HPV-18.
  • In benign HPV-related diseases such as genital warts or recurrent respiratory papillomatosis HPV-6 and 11, the two most frequent non-oncogenic types, are the predominant types detected.
  • We summarize the evidence linking HPV in the epidemiology and etiology of cancers of the vulva, vagina, anus and oropharynx and present recent estimates of the burden of and HPV type distribution in genital warts and in cases of HPV infection of the airways.
  • [MeSH-minor] Anus Neoplasms / virology. Female. Humans. Male. Papillomaviridae / immunology. Papillomaviridae / pathogenicity. Respiratory Tract Infections / epidemiology. Respiratory Tract Infections / virology. Uterine Cervical Diseases / epidemiology. Uterine Cervical Diseases / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18847554.001).
  • [ISSN] 0264-410X
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098803
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 91
  • [Other-IDs] NLM/ NIHMS73638; NLM/ PMC4366004
  •  go-up   go-down


58. McGhee EM, Cotter PD, Weier JF, Berline JW, Turner MA, Gormley M, Palefsky JM: Molecular cytogenetic characterization of human papillomavirus16-transformed foreskin keratinocyte cell line 16-MT. Cancer Genet Cytogenet; 2006 Jul 1;168(1):36-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular cytogenetic characterization of human papillomavirus16-transformed foreskin keratinocyte cell line 16-MT.
  • Anogenital cancers are closely associated with human papillomavirus (HPV), and HPV-infected individuals, particularly those with high-grade dysplasias, are at increased risk for cervical and anal cancers.
  • To address this, we examined an HPV16-transformed foreskin keratinocyte cell line, 16-MT, by GTG-banding, spectral karyotyping (SKY), and array comparative genomic hybridization (array CGH); these analyses revealed multiple numerical, complex, and cryptic chromosome rearrangements.
  • The 16-MT cell line showed losses and gains of DNA due to unbalanced translocations and complex rearrangements of regions containing known tumor suppressor genes.
  • Chromosomal changes in these regions might explain the increased risk of cancer associated with HPV.
  • These results provide the basis for the identification of candidate oncogenes responsible for cervical and anal cancer in amplified regions, and for putative tumor suppressor genes in commonly deleted regions like 11q22-23.
  • Furthermore, these data represent the first full characterization of the HPV-positive cell line 16-MT.
  • [MeSH-major] Cell Transformation, Viral / genetics. Human papillomavirus 16. Keratinocytes / virology
  • [MeSH-minor] Aneuploidy. Anus Neoplasms / genetics. Anus Neoplasms / virology. Cell Line, Transformed. Chromosome Aberrations. Chromosome Banding. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 19 / genetics. Chromosomes, Human, Pair 8 / genetics. Female. Humans. Infant, Newborn. Karyotyping. Male. Models, Biological. Penis. Telomerase / metabolism. Uterine Cervical Neoplasms / genetics. Uterine Cervical Neoplasms / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16772119.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA088739-05S1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


59. Kim JJ: Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis; 2010 Dec;10(12):845-52
HIV InSite. treatment guidelines - HIV InSite .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A vaccine targeting human papillomavirus (HPV) types 16 and 18, which are associated with 80% of anal cancers, is efficacious in men.
  • METHODS: I constructed decision-analytic models to estimate the direct health and economic outcomes of HPV vaccination (against types 6, 11, 16, and 18) for prevention of HPV-related anal cancer and genital warts.
  • I used the models to conduct sensitivity analyses, including duration of vaccine protection, vaccine cost, and burden of anal cancer and genital warts.
  • Outcomes were most sensitive to variations in anal cancer incidence, duration of vaccine protection, and HIV prevalence in MSM.
  • INTERPRETATION: HPV vaccination of MSM is likely to be a cost-effective intervention for the prevention of genital warts and anal cancer.
  • FUNDING: US National Cancer Institute.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Lancet. 2007 Jun 2;369(9576):1861-8 [17544766.001]
  • [Cites] J Public Health (Oxf). 2008 Sep;30(3):293-304 [18559368.001]
  • [Cites] Med Decis Making. 2002 Sep-Oct;22(5):417-30 [12365484.001]
  • [Cites] Clin Infect Dis. 2003 Jun 1;36(11):1397-403 [12766834.001]
  • [Cites] Value Health. 2004 Sep-Oct;7(5):518-28 [15367247.001]
  • [Cites] Med Decis Making. 1993 Apr-Jun;13(2):89-102 [8483408.001]
  • [Cites] Med Care. 1998 Jun;36(6):778-92 [9630120.001]
  • [Cites] J Infect Dis. 2004 Dec 15;190(12):2070-6 [15551204.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2005 Jun 24;54(24):597-601 [15973239.001]
  • [Cites] Med Decis Making. 2005 Nov-Dec;25(6):667-77 [16282217.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/35-41 [16950016.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):7-28 [17237032.001]
  • [Cites] MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24 [17380109.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1928-43 [17494926.001]
  • [Cites] Curr Opin HIV AIDS. 2009 Jan;4(1):57-63 [19339940.001]
  • [Cites] Sex Transm Dis. 2009 Aug;36(8):515-21 [19543143.001]
  • [Cites] Lancet. 2009 Jul 25;374(9686):301-14 [19586656.001]
  • [Cites] Curr Med Res Opin. 2009 Oct;25(10):2343-51 [19650749.001]
  • [Cites] BMJ. 2009;339:b3884 [19815582.001]
  • [Cites] Health Econ. 2010 Apr;19(4):422-37 [19382128.001]
  • [Cites] J Adolesc Health. 2010 Apr;46(4 Suppl):S12-9 [20307839.001]
  • [Cites] Sex Transm Dis. 2010 Jun;37(6):399-405 [20473245.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2010 May 28;59(20):630-2 [20508594.001]
  • [Cites] BMJ. 2010;341:c3493 [20647284.001]
  • [Cites] Vaccine. 2010 Aug 31;28(38):6247-55 [20643092.001]
  • [Cites] Hum Vaccin. 2009 Oct;5(10):696-704 [19855170.001]
  • [Cites] Vaccine. 2010 Oct 4;28(42):6858-67 [20713101.001]
  • [Cites] Cancer. 2010 Dec 1;116(23):5507-16 [20672354.001]
  • [Cites] Sex Transm Infect. 2009 Apr;85(2):148-9 [19153110.001]
  • [Cites] Am J Obstet Gynecol. 2008 May;198(5):500.e1-7 [18455524.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] BMJ. 2008;337:a769 [18640957.001]
  • [CommentIn] Lancet Infect Dis. 2010 Dec;10(12):815-6 [21051294.001]
  • (PMID = 21051295.001).
  • [ISSN] 1474-4457
  • [Journal-full-title] The Lancet. Infectious diseases
  • [ISO-abbreviation] Lancet Infect Dis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA093435; United States / NCI NIH HHS / CA / R01 CA93435
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Other-IDs] NLM/ NIHMS561569; NLM/ PMC3982926
  •  go-up   go-down


60. Ortholan C, Ramaioli A, Peiffert D, Lusinchi A, Romestaing P, Chauveinc L, Touboul E, Peignaux K, Bruna A, de La Roche G, Lagrange JL, Alzieu C, Gerard JP: Anal canal carcinoma: early-stage tumors &lt; or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy. Int J Radiat Oncol Biol Phys; 2005 Jun 1;62(2):479-85
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy.
  • PURPOSE: To investigate the clinical history, management, and pattern of recurrence of very early-stage anal canal cancer in a French retrospective survey.
  • METHODS: The study group consisted of 69 patients with Stage Tis and T1 anal canal carcinoma < or =1 cm treated between 1990 and 2000 (12 were in situ, 57 invasive, 66 Stage N0, and 3 Stage N1).
  • Four patients developed local failure outside the initial tumor bed.
  • CONCLUSION: Most recurrences occurred after a long disease-free interval after treatment and often outside the initial tumor site.
  • These small anal cancers could be treated by RT using a small volume and moderate dose (40-50 Gy for subclinical lesions and 50-60 Gy for T1).
  • [MeSH-major] Anus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / physiology. Carcinoma in Situ / pathology. Carcinoma in Situ / radiotherapy. Carcinoma in Situ / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / radiotherapy. Carcinoma, Transitional Cell / surgery. Chi-Square Distribution. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy Dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890590.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Hwang HJ, Bestani C, Jiménez R, Masciángioli G, Gutiérrez A, Cartelli C, Rafailovici L, Barugel M, Rodríguez G, Méndez G: [Treatment of patients with squamous cell carcinoma of the anal canal in the last 20 years in a gastroenterology hospital]. Acta Gastroenterol Latinoam; 2005;35(2):94-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of patients with squamous cell carcinoma of the anal canal in the last 20 years in a gastroenterology hospital].
  • [Transliterated title] El tratamiento de los pacientes con carcinoma epidermoide del canal anal en los últimos 20 años en nuestro hospital.
  • Anal cancers compromise only 1.5% of all digestive tumors.
  • OBJECTIVE: To collect and analyze clinical data from the medical records of all consecutive patients with squamous cell carcinoma of the anal canal (SCCAC) treated by the Oncology Section in 20 years.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16127985.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


62. Edgren G, Sparén P: Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study. Lancet Oncol; 2007 Apr;8(4):311-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study.
  • Although it has been designed and tested mainly to protect against cervical lesions, it is also expected to be effective against other anogenital cancers.
  • Associations between HPV and vaginal, vulvar, and anal cancers are well established, but the full extent in terms of age and time since diagnosis of these associations is not well known.
  • Using national registration numbers, we linked this cohort to nationwide population, migration, cancer, and death registers.
  • The incidence rate ratios (IRRs) of vaginal, vulvar, anal, and rectal cancer in women with a history of a cervical intraepithelial neoplasm (CIN), grade 3, compared with women with no such history were estimated by use of multivariate Poisson regression.
  • FINDINGS: Women with a history of grade 3 CIN had increased risks of cancer of the vagina (6.74 [95% CI 5.24-8.56]), vulva (2.22 [1.79-2.73]), and anus (IRR 4.68 [3.87-5.62]).
  • No excess risk was found for rectal cancer.
  • For all four anatomical sites, the IRRs varied substantially with the amount of time that had elapsed since the date of first diagnosis of grade 3 CIN.
  • Analyses stratified by attained age during follow-up showed that the risk of cancer conferred by a history of diagnosis of grade 3 CIN was highly age dependent.
  • INTERPRETATION: This study confirms the known association between history of CIN, presumed HPV infection, and increased risk of cancers of the vagina, vulva, and anus by use of large and complete databases, but also shows that this risk varies both by the time from initial diagnosis of grade 3 CIN and by the age of the individual.
  • [MeSH-major] Anus Neoplasms / complications. Cervical Intraepithelial Neoplasia / complications. Genital Neoplasms, Female / complications. Uterine Cervical Neoplasms / complications


63. Subramonia Iyer S, Akl A: A review of the outcomes of patients with anal cancer enrolled in the Hurley Cancer Registry: 1987-2004. J Clin Oncol; 2009 May 20;27(15_suppl):e15131

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A review of the outcomes of patients with anal cancer enrolled in the Hurley Cancer Registry: 1987-2004.
  • : e15131 Background: This paper describes the outcomes of patients with anal cancer enrolled in the Hurley Cancer Registry.
  • The Hurley cancer registry was searched using diagnosis codes for anal cancer.
  • The records retrieved, were reviewed for demographic and pathologic details,cancer recurrence, and vital status at last follow up.
  • RESULTS: Over a period of 18 years (1987 - 2004), there were 36 patients enrolled in the registry, with a diagnosis of anal cancer.
  • Mean age at diagnosis was 59.3 (SD 17.6) years for males, and 64.6 (SD 13.8) years for females.
  • Squamous cell cancers were the most common: 27 / 36 (75%).
  • Three of the five (60%) recurrent cancers were associated with HIV infection.
  • Cumulative survival functions for the cohort were derived for the time points of 3-yrs and 5-yrs after diagnosis.
  • CONCLUSIONS: Among patients in the Hurley Cancer Registry, 1.
  • Squamous cell carcinoma is the commonest (75%) anal cancer.
  • 2. The risk of recurrence of anal cancer was 14% over 6-years, and 80% of recurrence was localised to the anal canal.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960904.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Kauh J, Koshy M, Gunthel C, Joyner MM, Landry J, Thomas CR Jr: Management of anal cancer in the HIV-positive population. Oncology (Williston Park); 2005 Nov;19(12):1634-8; discussion 1638-40, 1645 passim
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of anal cancer in the HIV-positive population.
  • Squamous cell anal cancer remains an uncommon entity; however, the incidence appears to be increasing in at-risk populations, especially those infected with human papillomavirus (HPV) and human immunodeficiency virus (HIV).
  • Given the ability to cure this cancer using synchronous chemoradiotherapy, management practices of this disease are critical.
  • This article considers treatment strategies for HIV-positive patients with anal cancer, including the impact on chemoradiation-induced toxicities and the role of highly active antiretroviral therapy in the treatment of this patient population.
  • Additional changes to the chemotherapy dosing, such as giving 5-FU continuously and decreasing mitomycin dose, are evaluated and considered in relation to radiation field sizes in an effort to reduce toxicity, maintain local tumor control, and limit need for colostomy.
  • The impact of the immune system in patients with HIV and squamous cell carcinoma of the anus and the associated response to therapy remains unknown.
  • Continued studies and phase III trials will be needed to test new treatment strategies in HIV-infected patients with squamous cell cancer of the anus to determine which treatment protocols provide the greatest benefits.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / epidemiology. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / therapy. HIV Infections / epidemiology
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active / methods. Combined Modality Therapy / methods. Comorbidity. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Risk Assessment. Survival Analysis. Treatment Outcome


65. Gorez E, Staumont G: [Epidermoid anal carcinoma]. Rev Prat; 2008 Oct 31;58(16):1783-92
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidermoid anal carcinoma].
  • [Transliterated title] Carcinome epidermoïde anal.
  • Epidermoid carcinoma of the anus is a rare cancer, and conventionally affects elderly women.
  • Main predisposing factors are sexually transmitted diseases and particularly human papillomavirus (HPV) infection, variety of sexual partners, smoking, homosexuality, history of uterine cervix cancer, and immunodepression.
  • Warning signs of anal cancer are often non-specific.
  • The evaluation assessment should include lung X-ray, abdominal CT scan, and often pelvis MNR or anal endosonography.
  • Key prognostic factors are infiltration of the initial tumour and presence of lymph node metastasis.
  • First-line treament of anal epidermoid carcinoma is radiotherapy, combined with chemotherapy for extensive forms.
  • [MeSH-major] Anus Neoplasms. Carcinoma, Squamous Cell
  • [MeSH-minor] Age Factors. Aged. Anal Canal / pathology. Biopsy. Combined Modality Therapy. Female. Homosexuality, Male. Humans. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Risk Factors. Sex Factors

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19143150.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


66. Brewster DH, Bhatti LA: Increasing incidence of squamous cell carcinoma of the anus in Scotland, 1975-2002. Br J Cancer; 2006 Jul 3;95(1):87-90
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increasing incidence of squamous cell carcinoma of the anus in Scotland, 1975-2002.
  • In Scotland, since 1975-1979 (world) age-standardised incidence of squamous cell carcinoma of the anus has more than doubled, reaching 0.37 per 100,000 in males and 0.55 in females during 1998-2002, being somewhat higher in socioeconomically deprived areas.
  • [MeSH-major] Anus Neoplasms / epidemiology. Carcinoma, Squamous Cell / epidemiology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):61-4 [12085257.001]
  • [Cites] J Natl Cancer Inst. 1984 Mar;72(3):609-15 [6583444.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):611-6 [3524788.001]
  • [Cites] IARC Sci Publ. 1987;(82):1-406 [3329634.001]
  • [Cites] Acta Chir Scand. 1989 Mar;155(3):191-7 [2741627.001]
  • [Cites] J Public Health Med. 1991 Nov;13(4):318-26 [1764290.001]
  • [Cites] BMJ. 1993 Feb 13;306(6875):419-22 [8461721.001]
  • [Cites] Lancet. 1994 Mar 12;343(8898):636-9 [7906812.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Feb 1;11(2):178-82 [8556400.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Ann Transplant. 1997;2(4):59-66 [9869880.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 21;91(8):708-15 [10218509.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] Sex Transm Dis. 2005 May;32(5):314-20 [15849533.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):630-1 [15870433.001]
  • [Cites] Sex Transm Infect. 2005 Oct;81(5):367-72 [16199733.001]
  • [Cites] Am J Surg. 2005 Nov;190(5):732-5 [16226949.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):451-5 [16280701.001]
  • [Cites] Sex Health. 2004;1(3):137-40 [16335300.001]
  • [Cites] Eur J Cancer. 2002 Feb;38(3):414-7 [11818208.001]
  • [Cites] Dan Med Bull. 2002 Aug;49(3):194-209 [12238281.001]
  • [Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):505-7 [12888821.001]
  • [Cites] Cancer Causes Control. 2003 Nov;14(9):837-46 [14682441.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [ErratumIn] Br J Cancer. 2006 Aug 7;95(3):423
  • (PMID = 16721368.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2360500
  •  go-up   go-down


67. Buchs NC, Allal AS, Morel P, Gervaz P: Prevention, chemoradiation and surgery for anal cancer. Expert Rev Anticancer Ther; 2009 Apr;9(4):483-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention, chemoradiation and surgery for anal cancer.
  • Management of patients with squamous cell carcinoma of the anus (SCCA) has remained virtually unchanged since the 1980s.
  • By contrast, the demographics of SCCA are evolving, with the emergence of a high-risk group of patients: HIV-positive male homosexuals are prone to develop anal intra-epithelial neoplasia and rapidly progress towards invasive SCCA.
  • By many aspects, anal cancer is similar to uterine cervix cancer - a sexually transmitted disease driven by oncogenic human papillomavirus (HPV) infection.
  • [MeSH-major] Anus Neoplasms. Carcinoma, Squamous Cell
  • [MeSH-minor] Adolescent. Alphapapillomavirus / pathogenicity. Carcinoma in Situ / surgery. Carcinoma in Situ / virology. Combined Modality Therapy. Female. HIV Infections / complications. Homosexuality, Male. Humans. Male. Papillomavirus Infections / prevention & control. Papillomavirus Vaccines. Radiotherapy, Adjuvant / adverse effects. Salvage Therapy. Surgical Flaps. Surgical Wound Dehiscence / etiology. Surgical Wound Dehiscence / prevention & control. Vaccination

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • HIV InSite. treatment guidelines - HIV InSite .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19374601.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Number-of-references] 66
  •  go-up   go-down


68. da Costa e Silva IT, Gimenez FS, Guimarães RA, Camelo RT, Melo MN, de Barros FS, Daumas A, Cabral CR, Guimarães EL: [Anal cytology as a screening method for early detection of anal cancer: are hydrophilic cotton smears really unsatisfactory?]. Acta Cir Bras; 2005 Jan-Feb;20(1):109-14
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal cytology as a screening method for early detection of anal cancer: are hydrophilic cotton smears really unsatisfactory?].
  • [Transliterated title] Citologia anal como método de rastreamento para a detecção precoce do cancer anal: esfregaços com algodão hidrófilo são mesmo insatisfatórios?
  • METHODS: 318 consecutive patients were examined at the Ambulatório Araújo Lima of Hospital Universitario Getúlio Vargas in the Anal Cancer Prevention Week and were sampled for the performance of analpap.
  • The ability of cotton in producing satisfactory anal cytologic readings as compared to dacron and cytologic brush was analised.

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15810472.001).
  • [ISSN] 0102-8650
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] POR
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Brazil
  •  go-up   go-down


69. Badin S, Iqbal A, Sikder M, Chang VT: Persistent pain in anal cancer survivors. J Cancer Surviv; 2008 Jun;2(2):79-83
MedlinePlus Health Information. consumer health - Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent pain in anal cancer survivors.
  • INTRODUCTION: Anorectal cancers are highly curable malignancies.
  • RESULTS: Two patients presented with painful anal lesions that were diagnosed as squamous cell carcinoma of the anus.
  • IMPLICATIONS FOR CANCER SURVIVORS: Treatment related lumbosacral plexopathy may be an unrecognized consequence of the successful treatment of anal carcinoma.
  • [MeSH-major] Anus Neoplasms / complications. Pain / epidemiology. Postoperative Complications / epidemiology. Survivors

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18648976.001).
  • [ISSN] 1932-2267
  • [Journal-full-title] Journal of cancer survivorship : research and practice
  • [ISO-abbreviation] J Cancer Surviv
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Rubio CA, Nilsson PJ: Squamous-cell carcinoma of the anus with high intratumoral lymphocytosis and its clinical implications. Anticancer Res; 2008 Jul-Aug;28(4C):2469-72
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous-cell carcinoma of the anus with high intratumoral lymphocytosis and its clinical implications.
  • BACKGROUND: It has been claimed that patients with squamous cell carcinoma of the anal canal (SCCAC) showing intraepithelial lymphocytes have a poor prognosis.
  • Between 5 and 15 years follow-up, all SCCAC/HTIL patients had survived, whereas during the same time interval 28 (10.4%) of the SCCAC patients without HTIL had died of their tumor.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Lymphocytes, Tumor-Infiltrating / pathology. Lymphocytosis / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18751436.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


71. Edelman S, Johnstone PA: Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities. Int J Radiat Oncol Biol Phys; 2006 Sep 1;66(1):206-11
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities.
  • PURPOSE: We report toxicity and survival data of human immunodeficiency virus (HIV)-infected men with anal carcinoma treated with combined modality therapy (CMT) of radiotherapy and concurrent chemotherapy.
  • METHODS AND MATERIALS: A retrospective review was performed on the records of 17 HIV-positive patients with anal squamous cell carcinoma treated with CMT at our institution between 1991 and 2004.
  • Chemotherapy consisted of 5-fluorouracil and either mitomycin C or cisplatin.
  • CONCLUSION: For HIV patients with anal carcinoma, CMT yields reasonable local control with significant acute complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. HIV Infections / complications

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16904522.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NIMHD NIH HHS / MD / 5P60-MD000525
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


72. Page BR, McDonald T, Gagnon P, Lu K, Thomas CR: A unique case of Hajdu-Cheney syndrome and squamous cell carcinoma of the anus. Colorectal Dis; 2009 Jun;11(5):535-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A unique case of Hajdu-Cheney syndrome and squamous cell carcinoma of the anus.
  • OBJECTIVE: Hajdu-Cheney syndrome (HCS), first described in 1948 by Hajdu and independently in 1965 by Cheney, is an extremely rare disorder characterized by severe and excessive bone resorption leading to osteoporosis, with a wide range of other systemic complications from connective tissue and bone dysplasia.
  • No articles exist in the current literature describing a case of HCS with concurrent carcinoma.
  • Here, we present a case of a 54-year-old nonimmune compromised woman with multiple stigmata of HCS and recently diagnosed anal squamous cell carcinoma.
  • METHOD: This is a case report of HCS and stage T3N0 squamous cell carcinoma of the anus.
  • CONCLUSIONS: We present a patient with HCS who developed anal squamous cell carcinoma.
  • The mechanism of HCS, which is still unknown, may either make patients more susceptible to carcinoma or may just be a reflection of the normal incidence of anal squamous cell carcinoma given attributable risk factors.
  • [MeSH-major] Anus Neoplasms / complications. Carcinoma, Squamous Cell / complications. Hajdu-Cheney Syndrome / complications


73. Uronis HE, Bendell JC: Anal cancer: an overview. Oncologist; 2007 May;12(5):524-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer: an overview.
  • Anal cancer is a rare tumor with an incidence that has been rising over the last 25 years.
  • HIV infection is also associated with anal cancer; there is a higher incidence in HIV-positive patients but the direct relationship between HIV and anal cancer has been difficult to separate from the prevalence of HPV in this population.
  • HIV infection is also associated with anal cancer; there are increasing numbers of HIV-positive patients being diagnosed with the disease.
  • Treatment of anal cancer prior to the 1970s involved abdominoperineal resection, but the standard of care is now concurrent chemoradiation therapy, with surgery reserved for those patients with residual disease.
  • We present a case of anal cancer followed by a general discussion of both risk factors and treatment.
  • [MeSH-major] Anus Neoplasms. Carcinoma, Squamous Cell
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / epidemiology. Adenocarcinoma / therapy. HIV Infections / complications. Humans. Male. Middle Aged. Neoplasm Staging. Papillomavirus Infections / complications. Risk Factors

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17522240.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 48
  •  go-up   go-down


74. Franceschi S, De Vuyst H: Human papillomavirus vaccines and anal carcinoma. Curr Opin HIV AIDS; 2009 Jan;4(1):57-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus vaccines and anal carcinoma.
  • PURPOSE OF REVIEW: To explore the possible role of current prophylactic vaccines against human papillomavirus (HPV) in the prevention of anal intraepithelial neoplasia and squamous cell carcinoma of the anus (SCCA).
  • A meta-analysis of 955 SCCA showed that HPV prevalence was 85%, i.e., similar to that in cervical carcinoma, with an even stronger predominance of HPV16.
  • In addition, more than 90% prevalence of HPV was found in anal intraepithelial neoplasia.
  • Answers to some still open questions, notably vaccine efficacy in men and HIV-infected individuals and willingness to expand vaccination programmes to both sexes, are essential to predict the ultimate impact of HPV vaccines on the prevention of cancerous and precancerous anal lesions.
  • [MeSH-major] Anus Neoplasms / prevention & control. Carcinoma in Situ / prevention & control. Carcinoma, Squamous Cell / prevention & control. HIV Infections / complications. Papillomavirus Infections / prevention & control. Papillomavirus Vaccines / therapeutic use

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19339940.001).
  • [ISSN] 1746-6318
  • [Journal-full-title] Current opinion in HIV and AIDS
  • [ISO-abbreviation] Curr Opin HIV AIDS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / Papillomavirus Vaccines
  • [Number-of-references] 56
  •  go-up   go-down


75. Dahl O, Fluge Ø: [Anal cancer]. Tidsskr Nor Laegeforen; 2008 Jan 17;128(2):198-200
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal cancer].
  • [Transliterated title] Analkreft.
  • BACKGROUND: Anal cancer is a rare condition in Norway (40-50 new cases annually).
  • Knowledge of symptoms and findings is a prerequisite for providing a diagnosis while it is still possible to offer effective treatment with minimal side effects.
  • RESULTS AND INTERPRETATION: General practitioners must routinely examine patients with symptoms from the anal region in order to distinguish anal cancer from common haemorrhoids.
  • Diagnosis and treatment is centralized to cancer clinics at the Universities.
  • The main treatment modality is radiation therapy combined with chemotherapy, while surgery is relevant when the tumour is not controlled or for local side effects.
  • [MeSH-major] Anus Neoplasms

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18202733.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 31
  •  go-up   go-down


76. Panther LA, Schlecht HP, Dezube BJ: Spectrum of human papillomavirus-related dysplasia and carcinoma of the anus in HIV-infected patients. AIDS Read; 2005 Feb;15(2):79-82, 85-6, 88, 91
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of human papillomavirus-related dysplasia and carcinoma of the anus in HIV-infected patients.
  • The incidence of human papillomavirus (HPV)-related anal squamous cell carcinoma is increasing.
  • It is likely that long-standing HIV-related immunosuppression plays a significant role in the pathogenesis of anal carcinoma; however, a direct HIV-HPV interaction has also been implicated.
  • Using cervical cancer prevention as a paradigm, anal Pap smear screening as part of routine HIV preventive care has been proposed to detect and treat precancerous anal lesions in the hope of decreasing anal cancer rates.
  • All HIV-positive patients with invasive cancer of the anal canal, particularly those with CD4+ cell counts greater than 200/microL and those receiving HAART, should be managed in the same manner as their HIV-negative counterparts.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. HIV Infections / epidemiology. Papillomaviridae / isolation & purification. Papillomavirus Infections / epidemiology. Precancerous Conditions / pathology


77. Lund JA, Wibe A, Sundstrom SH, Haaverstad R, Kaasa S, Myrvold HE: Anal carcinoma in mid-Norway 1970-2000. Acta Oncol; 2007;46(7):1019-26
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma in mid-Norway 1970-2000.
  • The treatment of anal carcinoma changed from surgery to chemoradiotherapy 20-25 years ago.
  • The aim of this observational study was to compare surgery with chemoradiotherapy with regard to side effects, local recurrence and survival during and after the implementation of a new treatment policy for anal carcinoma.
  • The study includes all 111 patients with anal carcinoma diagnosed between 1970 and 2000 in mid-Norway.
  • Late side effects were moderate after combined therapy; only one patient preferred getting a stoma due to radiation damage of the anal sphincter.
  • The change of strategy for anal cancer treatment from surgery to combined therapy has probably reduced local recurrence and improved survival.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma / therapy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17882558.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


78. van Lieshout A, Pronk A: [Increasing incidence of anal cancer in the Netherlands]. Ned Tijdschr Geneeskd; 2010;154:A1163
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Increasing incidence of anal cancer in the Netherlands].
  • Anal cancer is a rare malignancy with a rapidly rising incidence.
  • The most important risk factor for anal cancer is persistent infection with Human papillomavirus (HPV).
  • In the Netherlands, the incidence of anal cancer increased from 71 to 149 new patients each year over the period 1989-2006.
  • Not enough research has been done to date to clarify why the incidence of anal cancer is increasing.
  • [MeSH-major] Anus Neoplasms / epidemiology. Papillomavirus Infections / complications

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20456793.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 11
  •  go-up   go-down


79. Newsom-Davis T, Bower M: HIV-associated anal cancer. F1000 Med Rep; 2010;2:85

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated anal cancer.
  • HIV-associated anal carcinoma, a non-AIDS-defining cancer, is a human papillomavirus-associated malignancy with a spectrum of preinvasive changes.
  • The standardized incidence ratio for anal cancer in patients with HIV/AIDS is 20-50.
  • Algorithms for anal cancer screening include anal cytology followed by high-resolution anoscopy for those with abnormal findings.
  • Outpatient topical treatments for anal intraepithelial neoplasia include infrared coagulation therapy, trichloroacetic acid, and imiquimod.
  • The development of cost-effective national screening programs for HIV-associated anal cancer remains a challenge.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 1992 Apr 8;267(14):1892 [1548812.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 15;14(5):415-22 [9170415.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):896-905 [15956651.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):293-9 [15980688.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Dis Colon Rectum. 2006 Jan;49(1):36-40 [16283561.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] Arch Dermatol. 2006 Nov;142(11):1438-44 [17116834.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2007 Sep;21(8):1054-60 [17714124.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):56-61 [18156992.001]
  • [Cites] J Invest Dermatol. 2008 Aug;128(8):2078-83 [18273049.001]
  • [Cites] Int J STD AIDS. 2008 Feb;19(2):118-20 [18334066.001]
  • [Cites] Dis Colon Rectum. 2008 Jun;51(6):829-35; discussion 835-7 [18363070.001]
  • [Cites] J Public Health (Oxf). 2008 Sep;30(3):293-304 [18559368.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):884-90 [19114688.001]
  • [Cites] MMWR Recomm Rep. 2009 Apr 10;58(RR-4):1-207; quiz CE1-4 [19357635.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):474-9 [19779306.001]
  • [Cites] AIDS. 2010 Feb 20;24(4):535-43 [19926961.001]
  • [Cites] Br J Dermatol. 2010 Jun;162(6):1269-77 [20184584.001]
  • [Cites] AIDS. 2010 Jun 1;24(9):1307-13 [20442633.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] AIDS. 2001 Nov 9;15(16):2157-64 [11684935.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] AIDS. 2004 Jul 23;18(11):1561-9 [15238774.001]
  • [Cites] J Infect Dis. 2004 Dec 15;190(12):2070-6 [15551204.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):1042-54 [15868241.001]
  • [Cites] Am J Med. 2000 Jun 1;108(8):634-41 [10856411.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] Dis Colon Rectum. 1987 Oct;30(10):782-5 [3652891.001]
  • [Cites] Acta Pathol Microbiol Immunol Scand A. 1986 Sep;94(5):343-9 [3766143.001]
  • [Cites] JAMA. 1982 Apr 9;247(14):1988-90 [7062503.001]
  • [Cites] Sex Transm Infect. 2005 Apr;81(2):142-6 [15800092.001]
  • (PMID = 21283597.001).
  • [ISSN] 1757-5931
  • [Journal-full-title] F1000 medicine reports
  • [ISO-abbreviation] F1000 Med Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3026623
  •  go-up   go-down


80. Sueda K, Ikenaga M, Miyazaki M, Yasui M, Mishima H, Tsujie M, Omiya H, Miyamoto A, Hirao M, Takami K, Fujitani K, Nakamori S, Yoshida K, Tsujinaka T: [A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2656-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus].
  • He presented with an anal tumor with bilateral inguinal nodal metastasis and pain in the anus; the tumor was diagnosed as stage IIIb (cA1N2M0).
  • However, CT performed 2 years after the diagnosis showed a recurrence in the hilar and mediastinal lymph node.
  • The patient developed non-hematologic toxicity and died within 3 years of the diagnosis.
  • We report a case of squamous cell carcinoma of the anus with associated HIV infection.
  • [MeSH-major] Anus Neoplasms / complications. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / therapy. HIV Seropositivity / complications


81. Palefsky JM: Anal cancer prevention in HIV-positive men and women. Curr Opin Oncol; 2009 Sep;21(5):433-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer prevention in HIV-positive men and women.
  • PURPOSE OF REVIEW: The incidence of human papillomavirus-associated anal cancer is unacceptably high among HIV-positive men who have sex with men, and possibly in HIV-positive women.
  • Unlike most other malignancies occurring in the HIV-positive population, anal cancer is potentially preventable, using methods similar to those used to prevent cervical cancer in women.
  • This review discusses the issues around screening to prevent anal cancer.
  • RECENT FINDINGS: Recent studies show that the incidence of anal cancer has increased since the introduction of highly active antiretroviral therapy in this population and now exceeds the highest incidence of cervical cancer among women reported anywhere in the world.
  • SUMMARY: The high incidence of anal cancer among HIV-positive individuals must not be ignored, since it may be preventable.
  • Given the current evidence and analogy with the cervical cancer prevention model, many clinicians believe that identification and treatment of high-grade anal intraepithelial neoplasia to prevent anal cancer are warranted.
  • When the expertise to do so exists, this is a reasonable approach, particularly if coupled with efforts to optimize further screening and treatment approaches, as well as efforts to document the efficacy of high-grade anal intraepithelial neoplasia treatment to reduce the incidence of anal cancer.

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2002 Apr 24;287(16):2120-9 [11966387.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):474-9 [19779306.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1928-43 [17494926.001]
  • [Cites] Dis Colon Rectum. 2007 May;50(5):565-75 [17380365.001]
  • [Cites] Lancet. 2007 Jun 30;369(9580):2161-70 [17602732.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):56-61 [18156992.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Dis Colon Rectum. 2008 Jun;51(6):829-35; discussion 835-7 [18363070.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] J Invest Dermatol. 2008 Aug;128(8):2078-83 [18273049.001]
  • [Cites] Dis Colon Rectum. 2009 Feb;52(2):239-47 [19279418.001]
  • [Cites] Int J Cancer. 2009 May 15;124(10):2375-83 [19189402.001]
  • [Cites] MMWR Recomm Rep. 2009 Apr 10;58(RR-4):1-207; quiz CE1-4 [19357635.001]
  • [Cites] Br J Dermatol. 2009 Oct;161(4):904-9 [19466962.001]
  • [Cites] ANZ J Surg. 2006 Aug;76(8):715-7 [16916390.001]
  • (PMID = 19587592.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000079; United States / NCI NIH HHS / CA / CA088739-04S2; United States / NCI NIH HHS / CA / CA054053-10; United States / NCI NIH HHS / CA / R01 CA054053; United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / R01 CA088739; United States / NCI NIH HHS / CA / R01 CA088739-04S2; United States / NCRR NIH HHS / RR / M01 RR00079; United States / NCI NIH HHS / CA / R01CA 88739; United States / NCI NIH HHS / CA / R01 CA054053-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 17
  • [Other-IDs] NLM/ NIHMS202771; NLM/ PMC3415247
  •  go-up   go-down


82. Eng C: Anal cancer: current and future methodology. Cancer Invest; 2006 Aug-Sep;24(5):535-44
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer: current and future methodology.
  • Despite the small number of patients affected by carcinoma of the anal canal it remains one of the most challenging cancers to treat.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Carcinoma in Situ / drug therapy. Carcinoma in Situ / pathology. Carcinoma in Situ / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / therapeutic use. Clinical Trials as Topic. Fluorouracil / therapeutic use. HIV Infections / complications. Humans. Mitomycin / therapeutic use. Neoadjuvant Therapy. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm, Residual. Papillomavirus Infections / complications

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16939964.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 64
  •  go-up   go-down


83. Durães Lde C, Sousa JB: [Anal cancer and sexually transmitted diseases: what is the correlation?]. Rev Col Bras Cir; 2010 Aug;37(4):265-8
MedlinePlus Health Information. consumer health - Sexually Transmitted Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal cancer and sexually transmitted diseases: what is the correlation?].
  • [Transliterated title] Câncer anal e doenças sexualmente transmissíveis: qual a correlação?
  • OBJECTIVE: Anal cancer is a rare tumor, which incidence is influenced by sexual behavior.
  • The purpose of this paper is to verify the correlation between anal cancer and sexually transmitted diseases, such as HPV, HIV, Gonococci infection, Chlamydia infection, syphilis and others.
  • METHODS: All the internments due to anal cancer, HIV, HPV, syphilis, Gonococci infection, Chlamydia infection and other sexually transmitted diseases in public healthy in Brazil were collected at Datasus site between 1998 and 2007.
  • RESULTS: There was a high correlation between anal cancer and HPV admissions (r=0.98, p<0.001).
  • There was negative correlation between anal cancer and Gonococci infection admissions (r=-0.81, p=0.005) and anal cancer and Chlamydia infection (r=-0.74, p=0.014).
  • There was not statistic significant correlation between anal cancer and HIV admissions (r=0.40, p=0.245), between anal cancer and other sexually transmitted diseases (r=0.55, p=0.1), and between anal cancer and syphilis (r=-0.61, p=0.059).
  • CONCLUSION: There was a high positive correlation between anal cancer and HPV admissions in Brazil.
  • There were negative correlations between anal cancer and Gonococci infection and between anal cancer and Chlamydia infection admissions.
  • [MeSH-major] Anus Neoplasms / complications. Anus Neoplasms / epidemiology. Sexually Transmitted Diseases / complications. Sexually Transmitted Diseases / epidemiology

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21085842.001).
  • [ISSN] 1809-4546
  • [Journal-full-title] Revista do Colégio Brasileiro de Cirurgiões
  • [ISO-abbreviation] Rev Col Bras Cir
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


84. Moe MM, Askill C: Stridor: an unexpected complication from chemoradiotherapy for anal cancer. J R Coll Physicians Edinb; 2009 Dec;39(4):313-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stridor: an unexpected complication from chemoradiotherapy for anal cancer.
  • The treatment of choice for anal cancer is chemoradiotherapy.
  • We report a patient who developed stridor as a result of chemoradiotherapy for anal cancer and discuss the pathogenesis and potential consequences.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21152467.001).
  • [ISSN] 1478-2715
  • [Journal-full-title] The journal of the Royal College of Physicians of Edinburgh
  • [ISO-abbreviation] J R Coll Physicians Edinb
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


85. Herat A, Whitfeld M, Hillman R: Anal intraepithelial neoplasia and anal cancer in dermatological practice. Australas J Dermatol; 2007 Aug;48(3):143-53; quiz 154-5
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal intraepithelial neoplasia and anal cancer in dermatological practice.
  • Anal intraepithelial neoplasia is considered to be a precursor lesion of invasive anal cancer.
  • Human papillomaviruses are considered to be an important aetiological agent in both anal intraepithelial neoplasia and anal cancer.
  • Dermatologists are likely to encounter these conditions among the differential diagnoses to be considered in high-risk patients presenting with perianal and anal lesions.
  • Anal cancer rates are also increasing among the HIV-infected and HIV-non-infected population.
  • The successful treatment of anal intraepithelial neoplasia may reduce the risk of subsequent development of anal cancer.
  • However, current therapies for anal intraepithelial neoplasia may be associated with treatment-related morbidity and are not well validated.
  • It is currently not proven that they reduce the likelihood of the development of anal cancer.
  • Nevertheless, screening for anal intraepithelial neoplasia is being advocated for high-risk groups and may become standard dermatological care for these patients.
  • In view of recent developments in the understanding of this condition, this article reviews the current understanding of anal intraepithelial neoplasia and its treatment from a dermatological perspective.
  • [MeSH-major] Anus Neoplasms. Carcinoma in Situ. Carcinoma, Squamous Cell. Papillomavirus Infections
  • [MeSH-minor] Diagnosis, Differential. HIV Infections / complications. Humans. Papillomaviridae / pathogenicity

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17680964.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 115
  •  go-up   go-down


86. Sato H, Maeda K, Koide Y, Matsuoka H, Noro T, Honda K, Shiota M, Endo T, Ozeki S, Fukuda M: [Four cases of anal squamous cell carcinoma treated by chemoradiotherapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2647-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Four cases of anal squamous cell carcinoma treated by chemoradiotherapy].
  • We reviewed clinical records of 4 cases with squamous cell carcinoma in anus to evaluate the clinical effectiveness of the chemoradiotherapy.
  • Three patients had T2 tumor, and one patient had T1 tumor.
  • All patients had complete response in the anal lesion after chemoradiotherapy.
  • No patients had any sign of recurrence in anal lesion.
  • Chemoradiotherapy was expected to be a safe and effective treatment to improve prognosis for anal squamous carcinoma.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224667.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


87. D'Souza G, Wiley DJ, Li X, Chmiel JS, Margolick JB, Cranston RD, Jacobson LP: Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr; 2008 Aug 1;48(4):491-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study.
  • OBJECTIVE: To examine the incidence and risk factors for anal cancer in a multicenter cohort of human immunodeficiency virus (HIV) positive and HIV-negative men who have sex with men followed between 1984 and 2006 (Multicenter AIDS Cohort Study).
  • RESULTS: There were 28 cases of anal cancer among the 6,972 men who were evaluated.
  • Among HIV-positive men, anal cancer incidence was higher in the highly active antiretroviral therapy (HAART) era than the pre-HAART era (incidence rate = 137 vs 30 per 100,000 person-years).
  • In multivariate analysis restricted to the HAART era, anal cancer risk increased significantly with HIV infection (relative hazard = 4.7, 95% confidence interval = 1.3 to 17) and increasing number of unprotected receptive anal sex partners at the first 3 study visits (P trend = 0.03).
  • Among HIV-positive men, current HAART use did not decrease anal cancer risk.
  • CONCLUSIONS: HIV-positive men had increased risk of anal cancer.
  • Improved survival of HIV-positive individuals after HAART initiation may allow for sufficient time for human papillomavirus-associated anal dysplasias to develop into malignancies, thus explaining the increased incidence of anal cancer in the HAART era.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] HIV Clin Trials. 2000 Jul-Aug;1(1):60-110 [11590490.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):61-4 [12085257.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):20-8 [12807941.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1517-23; discussion 1523-4; author reply 1524 [14605572.001]
  • [Cites] Cancer Causes Control. 2003 Nov;14(9):837-46 [14682441.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] J Infect Dis. 2004 Nov 1;190(9):1685-91 [15478076.001]
  • [Cites] Am J Epidemiol. 1987 Aug;126(2):310-8 [3300281.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] J Natl Cancer Inst. 1989 Nov 15;81(22):1726-31 [2810388.001]
  • [Cites] Clin Immunol Immunopathol. 1990 May;55(2):173-86 [1969782.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):180-9 [1311142.001]
  • [Cites] MMWR CDC Surveill Summ. 1992 Apr 24;41(2):1-7 [1594012.001]
  • [Cites] BMJ. 1993 Feb 13;306(6875):419-22 [8461721.001]
  • [Cites] Lancet. 1994 Mar 12;343(8898):636-9 [7906812.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 16;86(22):1711-6 [7966400.001]
  • [Cites] Am J Epidemiol. 1995 Aug 1;142(3):323-30 [7631636.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2540-6 [7595705.001]
  • [Cites] Am J Epidemiol. 1996 Nov 15;144(10):916-23 [8916502.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Aug 15;18(5):495-504 [9715847.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 21;91(8):708-15 [10218509.001]
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] J Natl Med Assoc. 2007 Dec;99(12):1386-94 [18229775.001]
  • [Cites] J Adolesc Health. 1999 Nov;25(5):328-35 [10551663.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):843-9 [11390533.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S42-8 [10430218.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2862-7 [15837733.001]
  • [Cites] Sex Transm Dis. 2005 May;32(5):314-20 [15849533.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):896-905 [15956651.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Colorectal Dis. 2005 Sep;7(5):492-5 [16108887.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):451-5 [16280701.001]
  • [Cites] Curr Opin Infect Dis. 2006 Feb;19(1):62-6 [16374220.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):303-15 [16507827.001]
  • [Cites] Am J Public Health. 2006 Jun;96(6):1020-7 [16670218.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/1-10 [16949995.001]
  • [Cites] Infect Dis Obstet Gynecol. 2006;2006 Suppl:40470 [16967912.001]
  • [Cites] AIDS Alert. 2006 Mar;21(3):22-3 [17378064.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • (PMID = 18614927.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI035042; United States / NIAID NIH HHS / AI / U01 AI037984; United States / NIAID NIH HHS / AI / UO1-AI-35042; United States / NIAID NIH HHS / AI / UO1-AI-37984; United States / NIAID NIH HHS / AI / UO1-AI-35040; United States / NIAID NIH HHS / AI / U01 AI037613; United States / NIAID NIH HHS / AI / UO1-AI-35041; United States / NCRR NIH HHS / RR / M01 RR000722; United States / NIAID NIH HHS / AI / U01 AI035041; United States / NIAID NIH HHS / AI / UM1 AI035043; United States / NIAID NIH HHS / AI / U01 AI035043; United States / NIAID NIH HHS / AI / UO1-AI-35039; United States / NIAID NIH HHS / AI / U01 AI035040; United States / NCRR NIH HHS / RR / 5-MO1-RR-00722; United States / NIAID NIH HHS / AI / U01 AI035039; United States / NIAID NIH HHS / AI / UO1-AI-35043; United States / NIAID NIH HHS / AI / UO1-AI-37613
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  • [Other-IDs] NLM/ NIHMS562648; NLM/ PMC3991563
  •  go-up   go-down


88. Mariani P, Ghanneme A, De la Rochefordière A, Girodet J, Falcou MC, Salmon RJ: Abdominoperineal resection for anal cancer. Dis Colon Rectum; 2008 Oct;51(10):1495-501
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdominoperineal resection for anal cancer.
  • PURPOSE: Following initial radiotherapy or chemoradiotherapy for the treatment of anal cancer, patients who present with either persistent or locally recurrent disease are treated by abdominoperineal resection.
  • METHODS: Over a 34-year period (1969-2003), 422 patients with nonmetastatic anal cancer were treated with a curative intent.
  • Using univariate analysis, patients below 55 years, females, T1-2 tumors, N0-N1 lymphadenopathy and the absence of locally advanced tumor were associated with significantly improved survival.
  • CONCLUSIONS: Abdominoperineal resection for nonmetastatic anal cancer is associated with a high morbidity rate but may result in long-term survival regardless of the indication.
  • [MeSH-major] Abdomen / surgery. Anus Neoplasms / surgery. Perineum / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18521675.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Rödel C: [Radiochemotherapy for locally advanced anal cancer]. Onkologie; 2010;33 Suppl 4:24-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiochemotherapy for locally advanced anal cancer].
  • [Transliterated title] Radiochemotherapie des lokal fortgeschrittenen Analkarzinoms.
  • Standard treatment for anal canal cancer is definitive radiochemotherapy (RCT) with 5-fluorouracil plus mitomycin C.
  • Because anal cancer overexpresses the epidermal growth factor receptor (EGFR), and a KRAS wild type is usually present, treatment with the EGFR antibody cetuximab is potentially interesting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Neoadjuvant Therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Humanized. Cetuximab. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cisplatin / adverse effects. Clinical Trials as Topic. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Gene Expression Regulation, Neoplastic / genetics. Humans. Mitomycin / administration & dosage. Mitomycin / adverse effects. Neoplasm Staging. Prognosis. Proto-Oncogene Proteins / genetics. Radiotherapy, Adjuvant. Receptor, Epidermal Growth Factor / genetics. ras Proteins / genetics

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20431309.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 50SG953SK6 / Mitomycin; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins; PQX0D8J21J / Cetuximab; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 13
  •  go-up   go-down


90. Contu SS, Agnes G, Damin AP, Contu PC, Rosito MA, Alexandre CO, Damin DC: Lack of correlation between p53 codon 72 polymorphism and anal cancer risk. World J Gastroenterol; 2009 Sep 28;15(36):4566-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of correlation between p53 codon 72 polymorphism and anal cancer risk.
  • AIM: To investigate the potential role of p53 codon 72 polymorphism as a risk factor for development of anal cancer.
  • METHODS: Thirty-two patients with invasive anal carcinoma and 103 healthy blood donors were included in the study. p53 codon 72 polymorphism was analyzed in blood samples through polymerase chain reaction-restriction fragment length polymorphism and DNA sequencing.
  • RESULTS: The relative frequency of each allele was 0.60 for Arg and 0.40 for Pro in patients with anal cancer, and 0.61 for Arg and 0.39 for Pro in normal controls.
  • CONCLUSION: These results do not support a role for the p53 codon 72 polymorphism in anal carcinogenesis.
  • [MeSH-major] Anus Neoplasms / genetics. Genes, p53

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2000 Aug;67(2):444-61 [10873790.001]
  • [Cites] Int J Cancer. 2009 May 15;124(10):2375-83 [19189402.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Oct;9(10):1037-42 [11045785.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):565-6 [11352871.001]
  • [Cites] Virchows Arch. 2001 Dec;439(6):782-6 [11787851.001]
  • [Cites] Cancer Lett. 2002 May 28;179(2):175-83 [11888672.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] J Clin Pathol. 2002 Oct;55(10):721-8 [12354793.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):357-65 [12567188.001]
  • [Cites] Am J Hum Biol. 2003 Nov-Dec;15(6):824-34 [14595874.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):196-9 [14639602.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):131-5 [14734461.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):11-22 [14744727.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(2):131-7 [14999143.001]
  • [Cites] Int J Gynaecol Obstet. 2004 Jun;85(3):301-8 [15145278.001]
  • [Cites] Mol Cell Biol. 1986 Dec;6(12):4650-6 [3025664.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] Science. 1989 Feb 17;243(4893):934-7 [2537532.001]
  • [Cites] Science. 1990 Apr 6;248(4951):76-9 [2157286.001]
  • [Cites] Nucleic Acids Res. 1990 Aug 25;18(16):4961 [1975675.001]
  • [Cites] Hum Hered. 1994 Sep-Oct;44(5):266-70 [7927355.001]
  • [Cites] Hum Hered. 1995 May-Jun;45(3):144-9 [7615299.001]
  • [Cites] Hum Hered. 1996 Jan-Feb;46(1):41-8 [8825462.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] Nature. 1998 May 21;393(6682):229-34 [9607760.001]
  • [Cites] J Mol Med (Berl). 1999 Feb;77(2):299-302 [10023783.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Jun;159(2):143-7 [15899386.001]
  • [Cites] Am J Hum Biol. 2005 Jul-Aug;17(4):496-506 [15981186.001]
  • [Cites] Cancer Detect Prev. 2006;30(6):523-9 [17113725.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Eur J Surg Oncol. 2007 Jun;33(5):569-74 [17321098.001]
  • [Cites] Int J Cancer. 2007 Aug 1;121(3):621-32 [17405118.001]
  • [Cites] Oral Oncol. 2008 Aug;44(8):798-804 [18234542.001]
  • [Cites] Oncol Rep. 2009 Mar;21(3):809-14 [19212643.001]
  • [Cites] Mol Cell Biol Res Commun. 2000 Jun;3(6):389-92 [11032762.001]
  • (PMID = 19777616.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Codon
  • [Other-IDs] NLM/ PMC2752002
  •  go-up   go-down


91. Crehange G, Bosset M, Lorchel F, Dumas JL, Buffet-Miny J, Puyraveau M, Mercier M, Bosset JF: Combining cisplatin and mitomycin with radiotherapy in anal carcinoma. Dis Colon Rectum; 2007 Jan;50(1):43-9
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combining cisplatin and mitomycin with radiotherapy in anal carcinoma.
  • PURPOSE: The European Organization for Research and Treatment of Cancer (EORTC) phase II study No. 22953 demonstrated the feasibility of reducing the overall treatment time of chemoradiation, delivering mitomycin C twice rather than once and fluorouracil during the whole treatment.
  • We tested the feasibility of chemoradiation in anal carcinoma with mitomycin and cisplatin in a phase II study.
  • METHODS: Twenty-one patients with locally advanced anal carcinoma (15 women, 6 men) were treated.
  • CONCLUSIONS: Combining radiation with mitomycin and cisplatin in patients with locally advanced anal cancer is feasible.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma / drug therapy. Carcinoma / radiotherapy. Cisplatin / administration & dosage. Mitomycin / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Drug Administration Schedule. Feasibility Studies. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy Dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17089083.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


92. Hatfield P, Cooper R, Sebag-Montefiore D: Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma. Int J Radiat Oncol Biol Phys; 2008 Feb 1;70(2):419-24
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma.
  • PURPOSE: To report the results of patients with early-stage anal cancer treated using a low-dose, reduced-volume, involved-field chemoradiotherapy protocol.
  • Of the 21 patients, 17 had had lesions that were excised with close (<1 mm) or involved margins, 1 had had microinvasive disease on biopsy, and 3 had had macroscopic tumor <2 cm in diameter (T1).
  • CONCLUSION: The results of our study have shown that for patients with anal carcinoma who have residual microscopic or very-small-volume disease, a policy of low-dose, reduced-volume, involved-field chemoradiotherapy produces excellent local control and disease-free survival, with low rates of acute and late toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / methods. Dose Fractionation. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17919842.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


93. Poggi MM, Suh WW, Saltz L, Konski AA, Mohiuddin M, Herman J, Johnstone PA: ACR Appropriateness Criteria on treatment of anal cancer. J Am Coll Radiol; 2007 Jul;4(7):448-56
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ACR Appropriateness Criteria on treatment of anal cancer.
  • Anal cancer is a relatively rare neoplasm, accounting for roughly 4,500 cases per year.
  • The evolution of the definitive treatment of anal cancer from a surgical to a nonsurgical approach, however, has been viewed as a model disease site in a larger paradigm shift in medicine.
  • Organ preservation, in this case a functional anal sphincter, and durable cure are obtainable goals.
  • To this end, anal cancer is a disease best treated primarily with chemoradiation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Mitomycin / therapeutic use. Neoplasm Staging. Predictive Value of Tests

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17601586.001).
  • [ISSN] 1558-349X
  • [Journal-full-title] Journal of the American College of Radiology : JACR
  • [ISO-abbreviation] J Am Coll Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


94. Kreuter A, Brockmeyer NH, Wieland U: [Anal intraepithelial neoplasia and anal carcinoma: an increasing problem in HIV patients]. Hautarzt; 2010 Jan;61(1):21-6
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal intraepithelial neoplasia and anal carcinoma: an increasing problem in HIV patients].
  • [Transliterated title] Anale intraepitheliale Neoplasie und Analkarzinom : Ein zunehmendes Problem bei Menschen mit HIV-Infektion.
  • Anal dysplasia is common in HIV patients, especially in HIV-positive men having sex with men (MSM).
  • High-grade anal dysplasia can progress to invasive anal cancer.
  • As in cervical carcinoma, there is a cause and effect relationship between anal cancer and human papillomavirus (HPV) infection, especially with high-risk types such as HPV16.
  • Several experts have recommended screening programs for anal cancer, including anal cytology along the lines of the Pap smear in women.
  • Clinical inspection, lesion biopsy, and treatment of anal dysplasia are performed under high-resolution anoscopy.
  • Anal cancer is divided into cancer of the anal margin and cancer of the anal canal.
  • Early cancer of the anal margin is excised akin to squamous cell cancer of the exposed skin, whereas cancer of the anal canal is treated by radiochemotherapy.
  • Physicians working in the field of HIV/AIDS should regularly screen their patients for the presence of anal dysplasia and anal cancer.
  • Basic diagnostic workup includes clinical inspection of the perianal area, digital rectal examination, and anal cytology.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / prevention & control. Carcinoma in Situ / virology. HIV Infections / complications. Precancerous Conditions / diagnosis. Precancerous Conditions / prevention & control

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19967333.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


95. Das P, Crane CH, Ajani JA: Current treatment for localized anal carcinoma. Curr Opin Oncol; 2007 Jul;19(4):396-400
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current treatment for localized anal carcinoma.
  • PURPOSE OF REVIEW: Chemoradiation represents the standard of care for most patients with localized squamous cell carcinoma of the anal canal.
  • This article reviews randomized trials and recent studies on chemoradiation for anal cancer.
  • Recent studies have started to evaluate intensity modulated radiation therapy for anal cancer, in an effort to reduce acute and long-term toxicity from radiotherapy.
  • SUMMARY: The role of cisplatin in anal cancer is not completely clear, although an ongoing randomized trial (Anal Cancer Trial II) may help clarify the role of cisplatin.
  • Studies on tumor biology and patient genetics are warranted to identify patients that are most likely to benefit from newer locoregional and systemic therapies.
  • Intensity modulated radiation therapy appears to be a promising approach for reducing treatment-related toxicity in anal cancer patients.
  • The Radiation Therapy Oncology Group (RTOG) is conducting a phase II trial evaluating the multi-institutional feasibility of intensity modulated radiation therapy for anal cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Carcinoma, Squamous Cell / drug therapy. Cisplatin / therapeutic use. Radiation-Sensitizing Agents / therapeutic use

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17545807.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Sensitizing Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 21
  •  go-up   go-down


96. Sendagorta E, Herranz P, Guadalajara H, Zamora FX, Gonzalez J: Anal carcinoma in an HIV-infected woman. ScientificWorldJournal; 2010;10:986-7
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma in an HIV-infected woman.
  • A 42-year-old HIV-infected woman with an antecedent of HPV-related genital disease is diagnosed with invasive anal carcinoma due to HPV 16.
  • Anal cancer is becoming an increasing problem in HIV-infected woman.
  • In fact, the prevalence of HPV infection-related disease in this population is higher in the anus than in the cervix.
  • [MeSH-major] Anus Neoplasms / complications. HIV Infections / complications. Papillomavirus Infections / complications. Tumor Virus Infections / complications

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20526528.001).
  • [ISSN] 1537-744X
  • [Journal-full-title] TheScientificWorldJournal
  • [ISO-abbreviation] ScientificWorldJournal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


97. Wu M, Zhang SW, Han RQ, Zhou JY, Zou XN, Chen WQ: [Analysis on the mortality of colorectal and anal cancer in China during 2004 - 2005]. Zhonghua Yu Fang Yi Xue Za Zhi; 2010 May;44(5):403-7
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis on the mortality of colorectal and anal cancer in China during 2004 - 2005].
  • OBJECTIVE: To describe the mortality of colorectal and anal cancer in the Chinese population during 2004 - 2005.
  • METHODS: Mortality of colorectal and anal cancer from The 3rd National Death Retrospective Sampling Survey (2004 - 2005) were analyzed, with that the total population was 142 660 482 person-year and the number of death cases was 10 586.
  • Crude death rate, age-standardized death rate by Chinese standard population (CASR) and world standard population (WASR), the constitute proportion to all cancer deaths and rank of cancer death were calculated and compared with The 1st (during 1973 - 1975) and The 2nd (during 1990 - 1992) National Death Retrospective Surveys.
  • RESULTS: The mortality of colorectal and anal cancer in China was 7.42/100 000 (10 586/142 660 482) during 2004 - 2005, accounting for 5.46% of total cancer deaths and ranked the 5th leading cause of death from cancer.
  • Compared to the crude death rate 5.30/100 000 and CASR 4.54/100 000 during 1990 - 1992, the crude death rate and CASR from colorectal and anal cancer increased by 40.00% and 5.51%, whereas compared to the crude death rate 4.17/100 000 and CASR 4.27/100 000 during 1973 - 1975, the crude death rate and CASR had increased by 77.94% and 12.18% respectively.
  • CONCLUSION: The mortality of colorectal and anal cancer has been increasing rapidly in China.
  • [MeSH-major] Anus Neoplasms / mortality. Colorectal Neoplasms / mortality

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20654228.001).
  • [ISSN] 0253-9624
  • [Journal-full-title] Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
  • [ISO-abbreviation] Zhonghua Yu Fang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


98. Goéré D, Bonnet S, Pocard M, Deutsch E, Lasser P, Elias D: Oncologic and functional results after abdominoperineal resection plus pseudocontinent perineal colostomy for epidermoid carcinoma of the anus. Dis Colon Rectum; 2009 May;52(5):958-63
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncologic and functional results after abdominoperineal resection plus pseudocontinent perineal colostomy for epidermoid carcinoma of the anus.
  • PURPOSE: Surgical treatment for epidermoid carcinoma of the anus is reserved for patients after failure of primary chemoradiotherapy and consists of abdominoperineal resection with permanent iliac colostomy.
  • The purpose of this study was to analyze the oncologic and the functional outcomes after abdominoperineal resection and pseudocontinent perineal colostomy for epidermoid carcinoma of the anus after external radiation at maximal doses (60 Gy).
  • METHODS: Between 1990 and 2006, 95 patients underwent abdominoperineal resection for an epidermoid carcinoma of the anus.
  • [MeSH-major] Abdomen / surgery. Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Colostomy / methods. Perineum / surgery

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19502862.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Gervaz P, Buchs N, Morel P: Diagnosis and management of anal cancer. Curr Gastroenterol Rep; 2008 Oct;10(5):502-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of anal cancer.
  • During the past three decades, anal cancer has served as a paradigm for the successful application of chemoradiation to solid tumors.
  • Since the early 1990s, the increasing incidence of anal cancer in homosexual men has highlighted the causative role of oncogenic human papilloma-virus infection.
  • This review focuses on significant trends and developments in the management of patients with squamous cell carcinoma of the anal canal, emphasizing three major aspects of diagnosis and treatment: routine screening and eradication of premalignant lesions in high-risk individuals; outcome of chemoradiation therapy in HIV-positive individuals in the era of highly active antiretroviral therapy; and potential improvements in chemoradiation protocols through improved radiation delivery technique and the combination of mitomycin with cisplatin in current prospective randomized trials.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18799127.001).
  • [ISSN] 1534-312X
  • [Journal-full-title] Current gastroenterology reports
  • [ISO-abbreviation] Curr Gastroenterol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


100. Abramowitz L, Rémy V, Vainchtock A: Economic burden of anal cancer management in France. Rev Epidemiol Sante Publique; 2010 Oct;58(5):331-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Economic burden of anal cancer management in France.
  • BACKGROUND: The incidence of anal cancer has increased over the last 25 years.
  • No organized screening exists for the precursors of anal cancer (anal intraepithelial neoplasia and carcinoma in situ) and diagnosis is often delayed.
  • Treatment for precursor lesions is of limited success, while cancer management is traumatic for the patient.
  • Like cancers of the cervix, most cases of anal cancer are associated with infection with human papillomavirus (HPV).
  • With increases in the incidence of anal cancer, and in light of the availability of prevention strategies such as screening and HPV vaccination, it is important, from a public health perspective, to assess the economic burden of anal cancer in France.
  • METHODS: We performed a retrospective analysis based on data extracted from a French hospital database - the Programme de médicalisation des systèmes d'information (PMSI) - to assess the number and management of patients hospitalized for anal cancer in 2006.
  • Data on radiotherapy sessions performed in private hospitals were obtained from the Statistiques annuelles des établissements de santé (SAE) database.
  • Costs of hospitalization, from the healthcare-payer perspective, were obtained from official diagnosis-related group tariffs for public and private hospitals.
  • RESULTS: In 2006, 3,711 patients with anal cancer were treated in hospitals in France.
  • The annual cost of hospital treatment for anal cancer was estimated at € 20,326,868.
  • CONCLUSION: This study, the first to investigate the economic burden of anal cancer in France, shows that the management costs of anal cancer are high and comparable to cervical cancer management costs (€ 44 million).
  • [MeSH-major] Anus Neoplasms / economics. Health Care Costs

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20869182.001).
  • [ISSN] 0398-7620
  • [Journal-full-title] Revue d'épidémiologie et de santé publique
  • [ISO-abbreviation] Rev Epidemiol Sante Publique
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  •  go-up   go-down






Advertisement